[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1735
1. Durand X, Vedrine L, Deligne E, Desfemmes FR, Ceccaldi B, Houlgatte A: [Management of testicular seminoma with elevation of alpha fetoprotein. A case report]. Prog Urol; 2008 Mar;18(3):190-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Prise en charge d'un séminome testiculaire avec élévation de l'alpha-foetoprotéine. A propos d'un cas.
  • Despite the absence of histological arguments after review of the slides, this lesion was considered to be a stage pT1 N3 M0 S3 non seminomatous germ cell tumour with a poor prognosis.
  • Simple surveillance was proposed following normalization of tumour markers, regression of retroperitoneal masses and negative PET scan.
  • The presence of embryonic carcinoma in one of the residual masses led to a revision of the initial histological diagnosis.
  • [MeSH-major] Seminoma / pathology. Testicular Neoplasms / pathology. alpha-Fetoproteins / analysis
  • [MeSH-minor] Adult. Antineoplastic Agents. Biomarkers, Tumor / blood. Humans. Lymph Node Excision. Male

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18472076.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


2. Bouffet E: The role of myeloablative chemotherapy with autologous hematopoietic cell rescue in central nervous system germ cell tumors. Pediatr Blood Cancer; 2010 Apr;54(4):644-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of myeloablative chemotherapy with autologous hematopoietic cell rescue in central nervous system germ cell tumors.
  • This review of the experience of high dose chemotherapy in patients with recurrent or refractory intracranial germ cell tumor confirms that sustained tumor control can be achieved with this modality both in germinoma and non-germinomatous germ cell tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Neoplasms, Germ Cell and Embryonal / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20146220.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


3. De Giorgi U: Is high-dose chemotherapy based on carboplatin, a late dose-intensification of a cisplatin-based salvage chemotherapy in germ cell tumour patients? Ann Oncol; 2006 Mar;17(3):530-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is high-dose chemotherapy based on carboplatin, a late dose-intensification of a cisplatin-based salvage chemotherapy in germ cell tumour patients?

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Oncol. 2005 Jul;16(7):1152-9 [15928070.001]
  • (PMID = 16282249.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase III; Comment; Letter; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Salem F, Rosenblum MK, Jhanwar SC, Kancherla P, Ghossein RA, Carlson DL: Teratocarcinosarcoma of the nasal cavity and paranasal sinuses: report of 3 cases with assessment for chromosome 12p status. Hum Pathol; 2008 Apr;39(4):605-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sinonasal teratocarcinosarcoma (SNTCS) is a rare malignant neoplasm with 63 reported cases to date.
  • Histologically, these tumors are characterized by the presence of admixed epithelial and mesenchymal components.
  • Two SNTCSs from the archives of Memorial Sloan-Kettering Cancer Center and one submitted from St Luke's-Roosevelt Hospital Center were evaluated by fluorescent in situ hybridization for amplification of chromosome12p, an event usually associated with the genesis of bona fide germ cell neoplasms (including mediastinal and testicular teratomas).
  • A malignant germ cell component was not identified in any of the cases.
  • Our findings suggest that 12p amplification, if it occurs at all in this setting, is exceptional and that SNTCS is a somatic-type neoplasm exhibiting divergent differentiation rather than a germ cell tumor.
  • [MeSH-major] Carcinosarcoma / etiology. Chromosome Aberrations. Chromosomes, Human, Pair 12 / genetics. Nasal Cavity. Nose Neoplasms / etiology. Paranasal Sinus Neoplasms / etiology. Teratocarcinoma / etiology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284932.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Fitzgerald JP, Ercole B, Parekh DJ: Management of post-chemotherapy residual mass in patients with metastatic nonseminomatous germ cell tumors of the testis. Indian J Urol; 2010 Jan-Mar;26(1):98-101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of post-chemotherapy residual mass in patients with metastatic nonseminomatous germ cell tumors of the testis.
  • The basis of treatment for advanced germ cell tumors is chemotherapy and surgical resection of residual disease.
  • Complete removal of all post-chemotherapy residual masses remains the standard of care in the treatment of advanced nonseminomatous germ cell tumors both within and outside of the retroperitoneum.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2009 Jan;55(1):217-24 [18926622.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4365-9 [17906201.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):569-73 [1312586.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1683-94 [2170590.001]
  • [Cites] J Urol. 1989 Mar;141(3):557-9 [2918591.001]
  • [Cites] Acta Radiol Diagn (Stockh). 1986 Mar-Apr;27(2):199-203 [3716866.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1329-34 [8055456.001]
  • [Cites] J Clin Oncol. 1993 Jul;11(7):1294-9 [8391067.001]
  • [Cites] Br J Urol. 1998 Feb;81(2):295-300 [9488075.001]
  • [Cites] Semin Urol Oncol. 1998 May;16(2):65-71 [9649229.001]
  • [Cites] Urol Clin North Am. 1998 Aug;25(3):479-84 [9728217.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1668-76 [11920527.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3310-7 [12947067.001]
  • [Cites] BJU Int. 2006 Jun;97(6):1221-4 [16686715.001]
  • [Cites] J Urol. 2007 Jan;177(1):331-4; discussion 334 [17162083.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1033-7 [17261854.001]
  • [Cites] BJU Int. 2007 May;99(5):993-7 [17437432.001]
  • [Cites] Urol Clin North Am. 2007 May;34(2):199-217; abstract ix [17484925.001]
  • [Cites] World J Urol. 2009 Aug;27(4):489-92 [19373472.001]
  • (PMID = 20535294.001).
  • [ISSN] 1998-3824
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2878447
  • [Keywords] NOTNLM ; Cancer / testis
  •  go-up   go-down


6. Canales BK, Lukasewycz SJ, Manivel JC, Pryor JL: Postradiotherapy intratesticular leiomyosarcoma. Urology; 2005 Sep;66(3):657
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiation-induced tumors of this type are rare, have a median latency of 10 years, and are usually dose dependent (around 5000 cGy).
  • After radical orchiectomy, patients should be followed up with serial germ cell tumor markers and imaging to monitor for metastatic spread.
  • [MeSH-major] Leiomyosarcoma / etiology. Neoplasms, Radiation-Induced. Testicular Neoplasms / etiology

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140103.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


7. May M, Gunia S, Siegsmund M, Kaufmann O, Helke C, Hoschke B, Wille AH: [Coincidence of testicular germ cell tumor and sarcoidosis: A diagnostic challenge]. Urologe A; 2006 Sep;45(9):1176-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Coincidence of testicular germ cell tumor and sarcoidosis: A diagnostic challenge].
  • [Transliterated title] Testikulärer Keimzelltumor und Sarkoidose: Eine diagnostische Herausforderung.
  • Sarcoidosis, a condition that can be combined with testicular cancer, should always be considered in the differential diagnosis.
  • [MeSH-major] Mediastinal Diseases / complications. Neoplasms, Germ Cell and Embryonal / complications. Sarcoidosis / complications. Seminoma / complications. Testicular Neoplasms / complications
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Male. Neoplasm Staging. Orchiectomy. Postoperative Complications / diagnosis. Postoperative Complications / pathology. Postoperative Complications / surgery. Sarcoidosis, Pulmonary / complications. Sarcoidosis, Pulmonary / pathology. Sarcoidosis, Pulmonary / surgery. Testis / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] South Med J. 2005 Sep;98(9):935-6 [16217990.001]
  • [Cites] Ann Oncol. 2001 Oct;12 (10 ):1485-8 [11762823.001]
  • [Cites] Cancer Treat Rev. 1986 Sep;13(3):147-56 [3536088.001]
  • [Cites] Hum Pathol. 1984 Apr;15(4):394-6 [6714970.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):321-5 [9602267.001]
  • [Cites] Br J Cancer. 1974 Mar;29(3):247-51 [4830144.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1188-94 [7537802.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):337-43 [9669817.001]
  • [Cites] Am J Med. 1990 Nov;89(5):651-6 [2173404.001]
  • [Cites] Ann Thorac Surg. 2003 Jul;76(1):208-12 [12842542.001]
  • [Cites] APMIS. 1991 Mar;99(3):282-90 [1708267.001]
  • [Cites] Lancet. 2004 Dec 18-31;364(9452):2230 [15610813.001]
  • (PMID = 16673125.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Lee D, Suh YL: Histologically confirmed intracranial germ cell tumors; an analysis of 62 patients in a single institute. Virchows Arch; 2010 Sep;457(3):347-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologically confirmed intracranial germ cell tumors; an analysis of 62 patients in a single institute.
  • This study was undertaken to document the clinicopathologic characteristics of histologically verified, primary intracranial germ cell tumors (GCTs), determine treatment outcomes, and to identify prognostic factors.
  • Germinomas and malignant non-germinomatous germ cell tumors were most prevalent in the pineal gland, suprasellar region, and basal ganglia, whereas teratomas dominated at other sites.
  • Five-year OSs in patients with normal tumor marker (alphaFP or betaHCG) and patients with elevated marker were 85.26% and 66.96%, respectively (P = 0.0568).
  • Patients with elevated tumor marker levels may appear to have poorer OS independent of histology.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1986;2(5):233-7 [3791280.001]
  • [Cites] J Neurosurg. 1985 Aug;63(2):155-67 [2991485.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):66-72 [9420074.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Neurol Med Chir (Tokyo). 2004 Jan;44(1):33-7 [14959935.001]
  • [Cites] Neuroradiology. 1998 Aug;40(8):507-11 [9763338.001]
  • [Cites] Childs Nerv Syst. 2008 Nov;24(11):1315-21 [18581122.001]
  • [Cites] Semin Surg Oncol. 1998 Jan-Feb;14(1):13-25 [9407627.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):975-7; discussion 977-8 [10526079.001]
  • [Cites] Oncologist. 2008 Jun;13(6):690-9 [18586924.001]
  • [Cites] J Neurooncol. 2009 Mar;92(1):87-98 [19020806.001]
  • [Cites] Br J Neurosurg. 1995;9(3):391-401 [7546360.001]
  • [Cites] Clin Neurosurg. 1985;32:351-83 [3905145.001]
  • [Cites] Oncologist. 2000;5(4):312-20 [10964999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):505-10 [9112445.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):545-51 [1848284.001]
  • [Cites] Childs Nerv Syst. 2002 Feb;18(1-2):30-7 [11935241.001]
  • [Cites] Pediatr Neurosurg. 1993 May-Jun;19(3):121-6 [8499324.001]
  • [Cites] Eur J Cancer. 1998 Jan;34(1):104-10 [9624246.001]
  • [Cites] Childs Nerv Syst. 2001 Sep;17(9):503-11 [11585322.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] Pediatr Blood Cancer. 2008 Dec;51(6):768-73 [18802946.001]
  • [Cites] Pediatr Neurosurg. 1990-1991;16(3):156-62 [1966857.001]
  • [Cites] Neuropathology. 2009 Apr;29(2):176-80 [18627482.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1212 [10561181.001]
  • [Cites] Can J Neurol Sci. 2008 Mar;35(1):79-84 [18380282.001]
  • [Cites] Childs Nerv Syst. 1997 Apr;13(4):225-8 [9202859.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1629-35 [6288220.001]
  • [Cites] Surg Neurol. 1992 Aug;38(2):114-20 [1509343.001]
  • [Cites] Acta Neuropathol. 1973;25(4):291-306 [4356228.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2908-15 [8918487.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2156-67 [16220552.001]
  • [Cites] Urology. 2007 Nov;70(5):1007.e13-5 [18068467.001]
  • [Cites] Childs Nerv Syst. 1990 Jan;6(1):3-7 [2178773.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):41-8 [9548340.001]
  • [Cites] J Neurooncol. 2002 Feb;56(3):251-9 [12061732.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1974 Nov;122(3):517-24 [4547917.001]
  • [Cites] Acta Neurochir (Wien). 1993;120(3-4):111-7 [7681619.001]
  • (PMID = 20652714.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Eggener SE, Carver BS, Sharp DS, Motzer RJ, Bosl GJ, Sheinfeld J: Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J Urol; 2007 Mar;177(3):937-42; discussion 942-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer.
  • PURPOSE: We evaluated the incidence, sites and histology of disease outside 5 modified retroperitoneal lymph node dissection templates for patients with low stage nonseminomatous germ cell tumors of the testis.
  • MATERIALS AND METHODS: Our cohort consisted of 500 consecutive patients with clinical stage I to IIA nonseminomatous germ cell tumors who underwent primary retroperitoneal lymph node dissection from 1989 to 2004.
  • We analyzed 191 patients with pathological stage II disease and defined the incidence of disease outside 5 modified retroperitoneal lymph node dissection templates, 3 described for open surgery (Testicular Tumor Study Group, Indiana University and Memorial Sloan-Kettering Cancer Center) and 2 for laparoscopic surgery (University of Innsbruck and The Johns Hopkins University).
  • Regardless of template, histological distribution of extra-template disease was not significantly different from in-template disease with approximately 90% viable germ cell tumor, 10% teratoma only and 20% with any teratoma.
  • CONCLUSIONS: A significant number of men with clinical stage I to IIA nonseminomatous germ cell tumors and retroperitoneal metastases have disease present outside the limits of modified templates, including 20% to 30% with chemoresistant teratomatous elements.
  • [MeSH-major] Lymph Node Excision. Lymph Nodes / pathology. Neoplasms, Germ Cell and Embryonal / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Cohort Studies. Humans. Male. Neoplasm Staging. Retroperitoneal Space. Retrospective Studies

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296380.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32-CA82088-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Kim L, Glantz M: Chemotherapeutic options for primary brain tumors. Curr Treat Options Oncol; 2006 Nov;7(6):467-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapeutic options for primary brain tumors.
  • Malignant gliomas are the most common primary brain tumors.
  • Despite intensive clinical investigation and many novel therapeutic approaches, treatment for most primary brain tumors remains inadequate.
  • Surgery and radiation remain the primary modalities of therapy for malignant brain tumors.
  • In addition to this encouraging progress, recent experience has shown that selected malignant brain tumors--for example, anaplastic oligodendrogliomas, primary central nervous system lymphomas, medulloblastomas, and intracranial germ cell tumors--are often highly responsive to chemotherapy.
  • Molecular genetic studies are becoming indispensable aids in the diagnosis and treatment of the malignant gliomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1987 Jul;56(1):89-90 [3620320.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Neurosurg. 1994 Aug;81(2):188-95 [8027800.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):635-43 [1548527.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] Neurosurgery. 1993 Mar;32(3):365-70; discussion 371 [8455760.001]
  • [Cites] Oncology (Williston Park). 1995 Jan;9(1):63-71; discussion 71, 75-6, 78 [7718442.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):127-37 [11325440.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):153-60 [12816721.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):9-17 [1572835.001]
  • [Cites] Arch Neurol. 2005 Oct;62(10):1595-600 [16216945.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Trends Genet. 1995 Oct;11(10):412-5 [7482768.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] Ann Neurol. 1988 Apr;23(4):360-4 [3382171.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1561-7 [9552066.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1580-90 [1875220.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):299-305 [16645720.001]
  • [Cites] Radiother Oncol. 2002 Sep;64(3):259-73 [12242114.001]
  • [Cites] J Neurosurg. 1992 May;76(5):741-5 [1564535.001]
  • [Cites] Ann Neurol. 1999 Aug;46(2):183-8 [10443883.001]
  • [Cites] Cancer. 1981 Feb 15;47(4):649-52 [6164465.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1141-5 [16603598.001]
  • [Cites] Ann Neurol. 1990 May;27(5):573-4 [2360797.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1281-8 [16525183.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):183-8 [16524945.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):602-7 [8814163.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Cancer. 1988 May 1;61(9):1862-6 [3355979.001]
  • [Cites] Acta Neuropathol. 1984;64(4):265-72 [6391068.001]
  • [Cites] J Clin Oncol. 2006 Mar 10;24(8):1246-52 [16525179.001]
  • [Cites] Neurology. 1994 Sep;44(9):1721-7 [7936304.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Anticancer Res. 1991 Mar-Apr;11(2):719-27 [2064325.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):91-5 [7815084.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Neurosurgery. 1994 Feb;34(2):213-9; discussion 219-20 [8177380.001]
  • (PMID = 17032559.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


11. Carver BS, Sheinfeld J: Germ cell tumors of the testis. Ann Surg Oncol; 2005 Nov;12(11):871-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germ cell tumors of the testis.
  • The multidisciplinary approach to the management of germ cell tumors of the testis has resulted in survival rates of > 90% overall.
  • This review summarizes the principal management of germ cell tumors of the testis, highlighting the indications for surgery, controversies surrounding the integration of surgery, and alternative management strategies.
  • [MeSH-major] Germinoma. Testicular Neoplasms
  • [MeSH-minor] Biomarkers, Tumor / blood. Humans. Lymph Node Excision. Male. Neoplasm Staging. Seminoma / radiotherapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184443.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 82
  •  go-up   go-down


12. Do HJ, Lee WY, Lim HY, Oh JH, Kim DK, Kim JH, Kim T, Kim JH: Two potent transactivation domains in the C-terminal region of human NANOG mediate transcriptional activation in human embryonic carcinoma cells. J Cell Biochem; 2009 Apr 15;106(6):1079-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two potent transactivation domains in the C-terminal region of human NANOG mediate transcriptional activation in human embryonic carcinoma cells.
  • The core embryonic stem cell transcription factors Oct4, Sox2, and Nanog are expressed in germ cell tumors (GCTs) and have been proposed to play a regulatory role in tumorigenesis.
  • Nanog is a novel homeobox-containing transcription factor that is expressed in pluripotent cells as well as GCTs.
  • To understand the molecular and functional role of human NANOG (hNANOG) in germ cells, mutagenesis of the C-terminal domain (CD) of hNANOG and transient transfection assays in NCCIT human embryonic carcinoma cells were carried out to identify critical transactivation motifs.
  • The results of the current study contribute to a better understanding of the complicated molecular machinery of stem cell transcription factors and their role in unregulated proliferation in germ cell tumorigenesis.
  • [MeSH-major] Embryonal Carcinoma Stem Cells / physiology. Homeodomain Proteins / metabolism. Transcriptional Activation
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Line. Genes, Reporter. Humans. Mice. Molecular Sequence Data. Protein Structure, Tertiary. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. Sequence Alignment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19229867.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / NANOG protein, human; 0 / Nanog protein, mouse; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


13. Kaur H, Bagga R, Saha SC, Gainder S, Srinivasan R, Adhya AK, Dhaliwal LK: Juvenile granulosa cell tumor of the ovary presenting with pleural effusion and ascites. Int J Clin Oncol; 2009 Feb;14(1):78-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile granulosa cell tumor of the ovary presenting with pleural effusion and ascites.
  • Juvenile granulosa cell tumor (GCT) is a rare tumor, and the majority (90%) are reported in the prepubertal or under-30-year age group, in contrast to the adult type, which is more common in the fifth decade.
  • Being solid tumors, they may be associated with ascites and pleural effusion (Meigs' syndrome), which resolve after surgical removal of the tumor.
  • Tumor markers for GCT are still investigational (inhibin) and of not much use in making a preoperative diagnosis, unlike in the case of germ cell tumors.
  • However, lymph node sampling is advocated for complete staging of these tumors, as a significant number of recurrences are reported in the retroperitoneum, as well as in incompletely staged patients.
  • In the present patient, because of the association of Meigs' syndrome, a preoperative diagnosis of benign tumors such as fibroma/thecoma was also considered.
  • We report this rare tumor with an aim of reviewing the diagnosis and management from the reported literature.
  • [MeSH-major] Ascites / etiology. Granulosa Cell Tumor / pathology. Meigs Syndrome / pathology. Ovarian Neoplasms / pathology. Pleural Effusion, Malignant / etiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Singapore Med J. 2001 May;42(5):203-7 [11513057.001]
  • [Cites] Korean J Intern Med. 2005 Mar;20(1):105-9 [15906965.001]
  • [Cites] Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):323-7 [9988794.001]
  • [Cites] Obstet Gynecol. 1978 Dec;52(6):718-23 [733139.001]
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):51-5 [10094880.001]
  • [Cites] Gynecol Oncol. 1995 Dec;59(3):405-8 [8522265.001]
  • [Cites] Gynecol Oncol. 2007 Feb;104(2):396-400 [17030354.001]
  • [Cites] Cancer. 1997 May 15;79(10):1951-5 [9149022.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):204-9 [15589602.001]
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):35-41 [10094877.001]
  • [Cites] Am J Obstet Gynecol. 2004 Jul;191(1):366-7 [15295395.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):484-8 [8774662.001]
  • [Cites] N Engl J Med. 1989 Sep 21;321(12):790-3 [2770810.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):338-44 [7705666.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):31-4 [16537089.001]
  • (PMID = 19225930.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Sirachainan N, Wongruangsri S, Kajanachumpol S, Pakakasama S, Visudtibhan A, Nuchprayoon I, Lusawat A, Phudhicharoenrat S, Shuangshoti S, Hongeng S: Folate pathway genetic polymorphisms and susceptibility of central nervous system tumors in Thai children. Cancer Detect Prev; 2008;32(1):72-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Folate pathway genetic polymorphisms and susceptibility of central nervous system tumors in Thai children.
  • The aim of the present study was to evaluate whether single nucleotide polymorphisms in the genes encoding enzymes of the folate pathway predispose to any CNS tumors in Thai children.
  • METHODS: In the present case-control study, we investigated these polymorphisms in genomic DNA from peripheral blood mononuclear cells in 73 Thai children with various types of central nervous system tumors and in 205 age and sex matched controls.
  • RESULTS: Thirty-one out of 73 patients were diagnosed with glial tumors (astrocytoma, oigodendroglioma and ependymoma), 28 with embryonal CNS tumors (medulloblastoma, pinealoblastoma and primitive neuroectodermal tumor), 13 with germ cell tumors and 1 with meningioma.
  • We found that the homozygous CC allele of MTHFR A1298C conferred an increased risk of embryonal CNS tumors (OR: 3.9; 95% CI: 1.3-11.4, p=0.02).
  • CONCLUSION: Our findings thus suggest that folate metabolism may play a role in the pathogenesis of certain specific subtypes of pediatric brain tumor in Thai children, especially embryonal CNS tumors.
  • [MeSH-major] Central Nervous System Neoplasms / genetics. Folic Acid / genetics. Folic Acid / metabolism. Polymorphism, Genetic

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18406541.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Transport Proteins; 0 / Reduced Folate Carrier Protein; 0 / SLC19A1 protein, human; 935E97BOY8 / Folic Acid; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.1.13 / 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


15. Treiyer A, Blanc G, Stark E, Haben B, Treiyer E, Steffens J: Prepubertal testicular tumors: frequently overlooked. J Pediatr Urol; 2007 Dec;3(6):480-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prepubertal testicular tumors: frequently overlooked.
  • OBJECTIVE: Prepubertal testicular tumors are fundamentally distinct from their adult counterparts.
  • We reviewed our 10-year, two-institution experience with respect to diagnosis and treatment.
  • MATERIAL AND METHODS: A retrospective review was performed of all testicular tumors diagnosed between 1996 and 2006 in males younger than 14 years.
  • RESULTS: Of 15 primary testicular tumors, eight (53%) were germ-cell tumors (three teratomas, two yolk sac tumors, one seminoma, one embryonic carcinoma and one choriocarcinoma), four (27%) tumor-like lesions (epidermoid cysts), two (13%) gonadal stromal tumors (a Leydig and a Sertoli cell tumor), and one (7%) gonadoblastoma with gonadal dysgenesis.
  • All boys were presented with a painless scrotal mass and four (27%) of them with elevated tumor markers.
  • At a mean 4-year follow-up no patient has presented with recurrent tumor in the residual or contralateral testicle.
  • Postoperative physical examination and scrotal ultrasound were obtained in 14 patients at a median follow-up of 48.2 months, and there was no evidence of tumor progression.
  • CONCLUSIONS: Benign teratoma and epidermoid cysts were the most common prepubertal testicular tumors.
  • Any suspicion of a testicular tumor warrants an inguinal approach to prevent scrotal violation of the tumor.
  • Our limited experience with testis-sparing procedures supports the current trends that organ-confined surgery should be performed for benign lesions such as teratoma, Leydig cell tumor and epidermoid cysts based on frozen biopsy findings.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947799.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Heaney JD, Nadeau JH: Testicular germ cell tumors in mice: new ways to study a genetically complex trait. Methods Mol Biol; 2008;450:211-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular germ cell tumors in mice: new ways to study a genetically complex trait.
  • Testicular germ cell tumors (TGCTs) are the most common cancer affecting young men.

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18370062.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA119623-02S1; United States / NCI NIH HHS / CA / F32 CA119623-01; United States / NCI NIH HHS / CA / F32 CA119623-02; United States / NCI NIH HHS / CA / CA119623-02; United States / NCI NIH HHS / CA / CA119623-01; United States / NCI NIH HHS / CA / F32 CA119623-02S1
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Goel RK, Norman RW, Gupta R: Dystrophic calcified nodule of the testicle: a case report. Can Urol Assoc J; 2007 Nov;1(4):402-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a 29-year-old man who presented with generalized right testicular pain.
  • A right radical orchiectomy was performed identifying a 1.8 x 0.8 x 0.9-cm intratesticular calcific lesion with no evidence of intratubular germ cell tumour and negative tumour markers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1999 Mar;123(3):244-6 [10086514.001]
  • [Cites] J Urol. 1965 Nov;94(5):592-5 [4954393.001]
  • [Cites] J Urol. 1996 Jul;156(1):85-8 [8648846.001]
  • [Cites] Arch Pathol Lab Med. 1995 Jan;119(1):96-9 [7802566.001]
  • [Cites] Br J Urol. 1979 Oct;51(5):413 [533604.001]
  • (PMID = 18542828.001).
  • [ISSN] 1911-6470
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2422998
  •  go-up   go-down


18. Iş G, Taş S, Corapcioğlu F, Fayda M: Is it destiny or just migration pathway theory? Familial germ cell tumor with the same histopathologic subtype in a father and son. Pediatr Neurosurg; 2009;45(2):160
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is it destiny or just migration pathway theory? Familial germ cell tumor with the same histopathologic subtype in a father and son.
  • [MeSH-major] Cell Movement. Fathers. Neoplasms, Germ Cell and Embryonal / genetics. Neoplasms, Germ Cell and Embryonal / pathology. Nuclear Family. Pinealoma / genetics. Pinealoma / pathology
  • [MeSH-minor] Child. Humans. Male. Testicular Neoplasms / etiology. Testicular Neoplasms / genetics. Testicular Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Pediatr Neurosurg. 2006;42(1):38-44 [16357500.001]
  • (PMID = 19321956.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


19. Farmakis D, Pectasides M, Pectasides D: Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors. Eur Urol; 2005 Sep;48(3):400-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
  • Testicular germ cell tumors represent the most frequent malignancy in young males aged 20-35 years.
  • The current conventional-dose salvage regimens of reference are the vinblastine-ifosfamide-cisplatin or etoposide-ifosfamide-cisplatin combinations, which are expected to cure approximately 25% of non-seminomatous germ-cell tumour patients.
  • Newer cytotoxic drugs, such as gemcitabine and oxaliplatin have also been proved effective, while other agents, such as temozolamide, or targeted therapies, such as trastuzumab in cases over-expressing HER2/neu (20% of relapsing germ-cell tumors) are currently under evaluation.
  • Seminomas have generally a better prognosis than non-seminomatous tumors and salvage therapy is expected to cure about 50% of all cases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Organoplatinum Compounds / administration & dosage. Paclitaxel / administration & dosage. Salvage Therapy. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15964136.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 47
  •  go-up   go-down


20. Rexer H: [Darbepoetin alfa (Aranesp) as supportive therapy in patients with germ cell tumors]. Urologe A; 2006 Aug;45(8):1017-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Darbepoetin alfa (Aranesp) as supportive therapy in patients with germ cell tumors].
  • [Transliterated title] Darbepoetin alfa (Aranesp) als Supportivtherapie bei Patienten mit Keimzelltumoren.
  • [MeSH-major] Anemia / prevention & control. Erythropoietin / analogs & derivatives. Neoplasms, Germ Cell and Embryonal / drug therapy

  • MedlinePlus Health Information. consumer health - Anemia.
  • Hazardous Substances Data Bank. DARBEPOETIN ALFA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896758.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Hematinics; 11096-26-7 / Erythropoietin; 15UQ94PT4P / Darbepoetin alfa
  •  go-up   go-down


21. Miocinovic R, Abaza R: Testicular seminoma presenting with duodenal perforation: a case report. J Med Case Rep; 2008;2:294
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Testicular neoplasms metastasizing to the retroperitoneum rarely involve the upper gastrointestinal tract.
  • CONCLUSION: Germ cell tumor diagnosis should be considered when an ulcerating small bowel mass is identified in a young man.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2005 Nov;12(11):871-80 [16184443.001]
  • [Cites] Clin Imaging. 1992 Jul-Sep;16(3):201-3 [1498708.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2001;13(6):455-7 [11824886.001]
  • [Cites] Urology. 1976 Sep;8(3):234-9 [987634.001]
  • [Cites] Urology. 2004 Aug;64(2):376-7 [15302504.001]
  • [Cites] Cancer. 1988 Jun 15;61(12):2566-70 [3365676.001]
  • (PMID = 18782436.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2546414
  •  go-up   go-down


22. Kumar R, Shandal V, Shamim SA, Halanaik D, Malhotra A: Clinical applications of PET and PET/CT in pediatric malignancies. Expert Rev Anticancer Ther; 2010 May;10(5):755-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The common childhood cancers are leukemia, CNS tumors, lymphomas, soft-tissue tumors (such as rhabdomyosarcoma and fibrosarcoma), neuroblastoma, malignant bone tumors, germ cell tumors with neoplasms of gonads and hepatic tumors.
  • PET and PET/CT has been found to be useful in, for example, CNS tumors, lymphomas, soft-tissue tumors, neuroblastoma, malignant bone tumors and germ cell tumors.
  • PET/CT has a limited role in early diagnosis, however, it plays an important role in initial staging, treatment response evaluation and detection of metastatic disease in these cancers.
  • PET/CT has a limited role in detection of lesions smaller than 5 mm, well-differentiated tumors and tumors with low metabolic rate.
  • [MeSH-major] Neoplasms / diagnosis. Neoplasms / therapy. Positron-Emission Tomography / trends. Tomography, X-Ray Computed / trends
  • [MeSH-minor] Age Factors. Child. Clinical Trials as Topic / methods. Clinical Trials as Topic / trends. Humans. Neoplasm Staging / methods

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20470007.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 67
  •  go-up   go-down


23. Mathew RM, Vandenberghe R, Garcia-Merino A, Yamamoto T, Landolfi JC, Rosenfeld MR, Rossi JE, Thiessen B, Dropcho EJ, Dalmau J: Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis. Neurology; 2007 Mar 20;68(12):900-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis.
  • OBJECTIVE: To report the presence of microscopic neoplasms of the testis in men with anti-Ma2-associated encephalitis (Ma2-encephalitis) and to discuss the clinical implications.
  • RESULTS: Among 25 patients with Ma2-encephalitis younger than 50 years, 19 had germ-cell tumors, and 6 had no evidence of cancer.
  • 1) demonstration of anti-Ma2 antibodies in association with MRI or clinical features compatible with Ma2-encephalitis, 2) life-threatening or progressive neurologic deficits, 3) age < 50 years, 4) absence of other tumors, and 5) new testicular enlargement or risk factors for germ-cell tumors, mainly cryptorchidism or ultrasound evidence of testicular microcalcifications.
  • All orchiectomy specimens showed intratubular-germ cell neoplasms unclassified type (IGCNU) and other abnormalities including microcalcifications, atrophy, fibrosis, inflammatory infiltrates, or hypospermatogenesis.
  • Ma2 was expressed by neoplastic cells in three of three patients examined.
  • CONCLUSIONS: In young men with Ma2-encephalitis, 1) the disorder should be attributed to a germ-cell neoplasm of the testis unless another Ma2-expressing tumor is found, 2) negative tumor markers, ultrasound, body CT, or PET do not exclude an intratubular germ-cell neoplasm of the testis, and 3) if no tumor is found, the presence of the five indicated criteria should prompt consideration of orchiectomy.

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Neurol. 2001 Sep;50(3):339-48 [11558790.001]
  • [Cites] Urology. 2001 Jun;57(6):1133-7 [11377326.001]
  • [Cites] Nat Clin Pract Neurol. 2006 Oct;2(10):566-72; quiz 573 [16990830.001]
  • [Cites] Eur Urol. 2002 Jun;41(6):651-4 [12074783.001]
  • [Cites] Eur Urol. 2003 May;43(5):516-21 [12705996.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):214-6 [12816728.001]
  • [Cites] N Engl J Med. 2003 Oct 16;349(16):1543-54 [14561798.001]
  • [Cites] Eur Radiol. 2003 Dec;13(12):2567-76 [14531010.001]
  • [Cites] Acta Oncol. 2004;43(2):212-4 [15163173.001]
  • [Cites] Am J Reprod Immunol. 2004 Jul;52(1):27-35 [15214939.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):935-40 [15223965.001]
  • [Cites] Brain. 2004 Aug;127(Pt 8):1831-44 [15215214.001]
  • [Cites] Brain. 2004 Oct;127(Pt 10):2331-8 [15361417.001]
  • [Cites] J Urol. 1980 Jul;124(1):105-7 [6106071.001]
  • [Cites] Stroke. 1988 Dec;19(12):1497-500 [3201508.001]
  • [Cites] N Engl J Med. 1990 Jun 28;322(26):1844-51 [2348838.001]
  • [Cites] J Pathol. 1993 Oct;171(2):83-98 [7506771.001]
  • [Cites] J Clin Ultrasound. 1996 May;24(4):197-202 [8727418.001]
  • [Cites] N Engl J Med. 1997 Jul 24;337(4):242-53 [9227931.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2866-72 [9256130.001]
  • [Cites] J Urol. 1998 Oct;160(4):1353-7 [9751353.001]
  • [Cites] J Reprod Immunol. 1999 Mar;42(2):107-26 [10221734.001]
  • [Cites] N Engl J Med. 1999 Jun 10;340(23):1788-95 [10362822.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8544-7 [15623637.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):368-71 [15725806.001]
  • [Cites] J Urol. 2005 May;173(5):1577-9 [15821489.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2006 Jan;77(1):111-3 [16361608.001]
  • [Cites] Neurology. 2006 Jul 11;67(1):146-9 [16832096.001]
  • [CommentIn] Neurology. 2007 Aug 14;69(7):709; author reply 709-10 [17698799.001]
  • [CommentIn] Neurology. 2007 Mar 20;68(12):887-8 [17372122.001]
  • (PMID = 17151337.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R56 CA089054; United States / NCI NIH HHS / CA / R01CA089054; United States / NCI NIH HHS / CA / R01 CA089054-05; United States / NCI NIH HHS / CA / CA089054-05; United States / NCI NIH HHS / CA / R01 CA089054
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Ma2 antigen; 0 / Nerve Tissue Proteins
  • [Other-IDs] NLM/ NIHMS24644; NLM/ PMC1909749
  •  go-up   go-down


24. Murugan P, Siddaraju N, Sridhar E, Soundararaghavan J, Habeebullah S: Unusual ovarian malignancies in ascitic fluid: a report of 2 cases. Acta Cytol; 2010 Jul-Aug;54(4):611-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ovarian tumors of germ cell and sex-cord stromal derivation rarely exfoliate malignant cells in serous effusions.
  • A precise tissue diagnosis in these cases may be possible on serous body fluid cytology with a combined clinical and cytopathologic approach.
  • CASES: Ascitic fluid samples from 2 young women aged 23 and 25 years presenting with abdominal mass were cytologically analyzed, with relevant histochemical and immunohistochemical stains performed on cell block/histologic sections.
  • However, subsequent histopathologic examination showed them to be yolk sac tumor (YST) and juvenile granulosa cell tumor (JGCT).
  • Following histopathologic diagnosis, cytologic materials were reviewed, which revealed certain features such as hyaline globules in YST and distinct tubular structures in JGCT.
  • These cytologic findings in view of the younger age of the patients should have prompted the correct diagnosis.
  • CONCLUSION: This study emphasizes the importance of a combined clinical and cytologic approach when dealing with serous body fluid materials from uncommon ovarian malignancies such as YST and JGCT.
  • This simple and systematic approach is of great practical value in identifying certain cytomorphologic features that may aid in correct diagnosis.
  • [MeSH-major] Ascites / pathology. Endodermal Sinus Tumor / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Female. Humans. Hyalin / metabolism. Immunohistochemistry. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20715666.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


25. Oosterhuis JW, Stoop H, Honecker F, Looijenga LH: Why human extragonadal germ cell tumours occur in the midline of the body: old concepts, new perspectives. Int J Androl; 2007 Aug;30(4):256-63; discussion 263-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Why human extragonadal germ cell tumours occur in the midline of the body: old concepts, new perspectives.
  • Hypotheses on the origin and distribution of extragonadal germ cell tumours (GCTs) and teratomas are briefly reviewed and revisited in the light of (i) new developments in the classification of GCTs, (ii) data on genomic imprinting of these neoplasms and (iii) the recent finding that germ cells can be derived from mouse and human embryonal stem (ES) cells.
  • Only the Type I (infantile teratomas/yolk sac tumours) and Type II GCTs (seminomatous tumours and non-seminomas) occur in the gonads and extragonadal localizations.
  • The data on genomic imprinting lend support to the hypothesis that they are derived from germ cells.
  • These precursor cells could have differentiated from ES cells in extragonadal localizations.
  • Their distribution along the midline of the body is still best explained by the migration of primitive germ cells during development.
  • The narrower distribution of the Type II than the Type I GCTs is probably due to the more strict conditions for survival and proliferation of primordial germ cells (PGCs)/gonocytes from which the Type II tumours originate, when compared with the precursor cells of Type I tumours, probably primitive germ cells closer to the ES cell.
  • The known niches in which the Type II tumours develop have in common that they contain feeder cells expressing stem cell factor (SCF) - the ligand for the SCF receptor c-KIT, involved in proliferation and survival of PGCs/gonocytes - and contain GBY including the gene TSPY.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology
  • [MeSH-minor] Animals. Embryonic Stem Cells / pathology. Embryonic Stem Cells / physiology. Genomic Imprinting. Humans. Male. Mice. Organ Specificity. Seminoma / genetics. Seminoma / pathology. Teratoma / pathology. Testicular Neoplasms / genetics. Testicular Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17705807.001).
  • [ISSN] 0105-6263
  • [Journal-full-title] International journal of andrology
  • [ISO-abbreviation] Int. J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


26. Kaufmann S, Sauter M, Schmitt M, Baumert B, Best B, Boese A, Roemer K, Mueller-Lantzsch N: Human endogenous retrovirus protein Rec interacts with the testicular zinc-finger protein and androgen receptor. J Gen Virol; 2010 Jun;91(Pt 6):1494-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The normal functions of these, if any, are unknown, but some HERV proteins have been implicated in cancers, in particular germ-cell cancers.
  • For instance, it has been documented that (i) patients with germ-cell tumours frequently produce antibodies against HERV proteins;.
  • (ii) transgenic mice expressing HERV-K (HML-2) rec are prone to testicular carcinoma in situ; and (iii) Rec can bind and suppress a guardian of germline stem-cell pluripotency, the promyelocytic leukaemia zinc-finger protein (PLZF).
  • Interactions occurred via the N- and C-terminal domains of Rec and the C-terminal DNA-binding zinc-finger domain of TZFP (aa 375-450).
  • The most intensely studied function of TZFP is that of a co-repressor of the activated androgen receptor (AR).
  • Thus, HERV-K (HML-2) Rec may function as an oncoprotein by de-repressing oncogenic transcription factors such as AR.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20147518.001).
  • [ISSN] 1465-2099
  • [Journal-full-title] The Journal of general virology
  • [ISO-abbreviation] J. Gen. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AR protein, human; 0 / ERVK-6 protein, human endogenous retrovirus; 0 / Receptors, Androgen; 0 / Repressor Proteins; 0 / TZFP protein, human; 0 / Viral Envelope Proteins
  •  go-up   go-down


27. Ueno S, Hirakawa H, Matsuda H, Tei E, Kaneko A, Ohta Y, Kajiwara H: A case of neonatal mature teratoma transformed to malignancy in the neck extending to the mouth floor. Tokai J Exp Clin Med; 2009 Dec;34(4):130-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Puncture and marsupialisation of the cyst could not relieve her symptom and the tumor was resected in three occasions and was diagnosed as mature teratoma without malignant component.
  • Biopsied specimen demonstrated the mass to be germ cell tumor with embryonal carcinoma and yolk sac tumor component.
  • Head and neck teratomas in children are mostly benign amenable to curative excision but its rarity and site and size of the tumor make its treatment challenging.
  • There exists a relationship between the age at diagnosis and outcome of a patient with teratoma and head and neck teratomas in neonate are mostly benign but should be removed completely as soon as the patient condition is stabilized to reduce the risk of malignant change.
  • [MeSH-major] Cell Transformation, Neoplastic. Head and Neck Neoplasms / secondary. Mouth Floor / pathology. Mouth Neoplasms / secondary. Teratoma / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21319013.001).
  • [ISSN] 2185-2243
  • [Journal-full-title] The Tokai journal of experimental and clinical medicine
  • [ISO-abbreviation] Tokai J. Exp. Clin. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


28. Savic D, Stankovic ZB, Djukic M, Mikovic Z, Djuricic S: Torsion of malignant ovarian tumors in childhood and adolescence. J Pediatr Endocrinol Metab; 2008 Nov;21(11):1073-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Torsion of malignant ovarian tumors in childhood and adolescence.
  • AIM: To investigate the frequency of torsion of malignant ovarian tumors in children and adolescents.
  • Presentation, tumor markers and pathology reports were evaluated.
  • We reviewed the literature on torsion of malignant ovarian tumors.
  • Histological findings of torsioned masses showed 69 non-neoplasms and 23 tumors, including five malignant.
  • Origin of the malignant disease included four germ cell tumors and one sex-cord stromal tumor.
  • The morphology index score for malignant tumors was > or = 7 in all five patients.
  • Tumor markers were elevated in 12 patients, including four of the patients with malignant tumors.
  • We found tumor origin for 11 previous reported patients with torsion of malignant ovarian tumor, including seven germ cell and four granulosa cell tumors.
  • CONCLUSION: Torsion of malignant ovarian tumors in pediatric and adolescent patients occurs very rarely, but it is nevertheless possible at any stage of disease.
  • The most common torsioned malignant ovarian tumors were of germ cell origin, in both premenarchal and postmenarchal girls.
  • A torsioned adnexal mass with index > or = 7 needs to be considered as a potential malignant tumor.
  • [MeSH-major] Granulosa Cell Tumor / complications. Neoplasms, Germ Cell and Embryonal / complications. Ovarian Neoplasms / complications. Torsion Abnormality / complications
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Menarche / physiology. Neoplasm Staging. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19189702.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Verdorfer I, Horst D, Höllrigl A, Susani M, Hartmann A, Rogatsch H, Mikuz G: Leydig cell tumors of the testis: a molecular-cytogenetic study based on a large series of patients. Oncol Rep; 2007 Mar;17(3):585-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leydig cell tumors of the testis: a molecular-cytogenetic study based on a large series of patients.
  • The genetic features of the uncommon Leydig cell tumors (LCT) are largely unknown.
  • Consequently, it is of great importance to elucidate the pathogenesis of testicular germ cell tumors by cytogenetic and molecular biological investigations.
  • The purpose of the present study was the examination of cytogenetic features of these tumors in a large series of LCT.
  • In most of the studied cases, the aberrant cell population was additionally defined by interphase fluorescence in situ hybridization (I-FISH).
  • [MeSH-major] DNA, Neoplasm / genetics. Leydig Cell Tumor / genetics. Testicular Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17273737.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


30. Lakmichi MA, Niang L, Tligui M, Traxer O, Cussenot O, Gattegno B, Thibault P, Sebe P: [Infertility and testicular seminoma]. Presse Med; 2007 Dec;36(12 Pt 1):1753-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient underwent testicular biopsies for infertility, which showed an intratubular germ cell tumor.
  • Tumor markers (beta HCG, alpha FP, LDH) were normal.
  • [MeSH-major] Infertility, Male / diagnosis. Seminoma. Testicular Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Biopsy. Carboplatin / administration & dosage. Carboplatin / therapeutic use. Humans. Male. Neoplasm Staging. Orchiectomy. Sperm Count. Testis / pathology

  • Genetic Alliance. consumer health - Seminoma.
  • Genetic Alliance. consumer health - infertility.
  • MedlinePlus Health Information. consumer health - Male Infertility.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17560758.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


31. Fritzsche FR, Kristiansen G, Frauenfelder T, Opitz I, Bode P, Moch H, Montani M: Large mixed germ cell tumor in a young patient presenting as an intrapulmonary mass. Pathol Res Pract; 2009;205(8):572-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large mixed germ cell tumor in a young patient presenting as an intrapulmonary mass.
  • We present the case of a 26-year-old man with a bland medical history, who presented to the general practitioner because of severe cough and dyspnea.
  • The chest X-ray revealed a massive organ-displacing tumor in the right chest not delineable from the mediastinum.
  • The subsequent needle core biopsy was diagnostic for a mixed germ cell tumor comprising immature teratoma and seminoma.
  • After an initially good response to chemotherapy, tumor markers and tumor size were progressive.
  • The right-sided pneumonectomy revealed an intrapulmonary tumor with cystic and solid components, hemorrhage, and necrosis with a tumor diameter of 18cm.
  • Histology confirmed a teratoma with mature and immature components accompanied by residual seminomatous tumor cells.
  • We describe this exceptional large intrapulmonary germ cell tumor and discuss the spectrum of such rare tumors.
  • [MeSH-major] Lung Neoplasms / pathology. Seminoma / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Disease Progression. Fatal Outcome. Humans. Male. Radiography, Thoracic. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201104.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


32. Sharp DS, Carver BS, Eggener SE, Kondagunta GV, Motzer RJ, Bosl GJ, Sheinfeld J: Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol; 2008 Dec 1;26(34):5524-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome and predictors of survival in late relapse of germ cell tumor.
  • PURPOSE: Late relapse (LR) of germ cell tumor (GCT) is a well recognized entity associated with poor survival.

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Aug 1;95(3):520-30 [12209744.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4365-9 [17906201.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):113-22 [12506179.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):131-5 [12620907.001]
  • [Cites] Br J Urol. 1993 Mar;71(3):326-35 [8386580.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1170-6 [7537800.001]
  • [Cites] Ann Oncol. 1997 Jan;8(1):41-7 [9093706.001]
  • [Cites] J Urol. 2005 Mar;173(3):824-9 [15711278.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2781-8 [15837993.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6549-55 [16170162.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6999-7004 [16192587.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):820-7 [16508636.001]
  • [Cites] J Urol. 2006 Jul;176(1):100-3; discussion 103-4 [16753380.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5503-11 [17158535.001]
  • [Cites] J Urol. 2007 Mar;177(3):937-42; discussion 942-3 [17296380.001]
  • [CommentIn] J Clin Oncol. 2008 Dec 1;26(34):5502-3 [18936469.001]
  • (PMID = 18936477.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082088; United States / NCI NIH HHS / CA / T32-CA82088
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2651099
  •  go-up   go-down


33. Skotheim RI, Autio R, Lind GE, Kraggerud SM, Andrews PW, Monni O, Kallioniemi O, Lothe RA: Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changes. Cell Oncol; 2006;28(5-6):315-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changes.
  • INTRODUCTION: Testicular germ cell tumors of adolescent and young adult men (TGCTs) generally have near triploid and complex karyotypes.
  • We analyzed 17 TGCTs, three precursor lesions, and the embryonal carcinoma cell lines, NTERA2 and 2102Ep, by comparative genomic hybridization microarrays (array-CGH), and integrated the data with transcriptome profiles of the same samples.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 12 / genetics. Gene Expression Regulation, Neoplastic. Genome, Human / genetics. Neoplasms, Germ Cell and Embryonal / genetics. Oligonucleotide Array Sequence Analysis / methods. Testicular Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. DNA, Neoplasm / genetics. Gene Dosage. Gene Expression Profiling. Genes, Neoplasm. Humans. Male. Nucleic Acid Hybridization. Reproducibility of Results. Up-Regulation / genetics


34. Isolan GR, Krayenbühl N, Mahmoud M, Al-Mefty O: A hemangioblastoma in the pineal region: case report. Neurosurgery; 2007 Aug;61(2):E423; discussion E423
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pineal region tumors comprise approximately 1% of central nervous system neoplasms.
  • A wide variety of tumors can affect this region, the most common being germ cell tumors, gliomas, and pineal cell tumors.
  • CLINICAL PRESENTATION: We describe the case of a patient with a symptomatic hemangioblastoma in the pineal region with no clinical criteria for von Hippel-Lindau disease.
  • INTERVENTION: A lateral suboccipital infratentorial supracerebellar approach was used to remove the tumor, which was attached to the quadrigeminal plate.
  • This case emphasizes the importance of the differential diagnosis of hemangioblastomas located in this region.
  • These tumors can be safely removed through surgery.

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762728.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Kim DS, Shim KW, Kim TG, Chang JH, Park YG, Choi JU: Pineal cavernous malformations: report of two cases. Yonsei Med J; 2005 Dec 31;46(6):851-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pineal hemorrhage only occurs in rare cases, and this known to have several different causes such as germ cell tumors, pineal cysts and vascular malformations, including the cavernous malformations.
  • Although the diagnosis of pineal cavernous malformation is not easy because of the extreme rareness of this condition, the presence of this lesion can be suspected based on its typical radiological findings. Case 1.
  • We operated and totally removed the tumor and the hemorrhages via an occipital-transtentorial approach. Case 2.
  • We operated and totally removed the tumor and the hemorrhages via an occipital-transtentorial approach.
  • In this study, we describe our experiences for the diagnosis of cavernous malformations in the pineal region with special emphasis on the radiological aspects and the clinical course of this disease.
  • [MeSH-minor] Adult. Angiography. Diplopia / diagnosis. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 1999 Apr;13(2):189-92 [10616590.001]
  • [Cites] Kaohsiung J Med Sci. 1999 Aug;15(8):498-503 [10518367.001]
  • [Cites] Neurochirurgie. 2000 Jun;46(3):286-94 [10854986.001]
  • [Cites] Br J Neurosurg. 2000 Apr;14(2):147-51 [10889892.001]
  • [Cites] Br J Neurosurg. 1998 Jun;12(3):274-6 [11013695.001]
  • [Cites] No Shinkei Geka. 2000 Oct;28(10):909-12 [11070913.001]
  • [Cites] Med Arh. 2000;54(5-6):307-9 [11219912.001]
  • [Cites] Surg Neurol. 2001 Jun;55(6):365-71 [11483199.001]
  • [Cites] J Clin Neurosci. 2001 Sep;8(5):416-20 [11535007.001]
  • [Cites] Hiroshima J Med Sci. 2001 Sep;50(3):75-7 [11720166.001]
  • [Cites] J Pediatr Endocrinol Metab. 2002 Sep-Oct;15(8):1195-201 [12387519.001]
  • [Cites] Can J Neurol Sci. 2003 Feb;30(1):67-71 [12619788.001]
  • [Cites] Stroke. 2003 May;34(5):1163-9 [12702837.001]
  • [Cites] J Neurosurg. 1981 Sep;55(3):484-7 [7196441.001]
  • [Cites] Neurosurgery. 1982 Apr;10(4):437-44 [7099393.001]
  • [Cites] No Shinkei Geka. 1985 Jun;13(6):641-5 [3840234.001]
  • [Cites] Am J Forensic Med Pathol. 1986 Mar;7(1):64-8 [3728423.001]
  • [Cites] Neuroradiology. 1989;31(2):187-9 [2747899.001]
  • [Cites] Childs Nerv Syst. 1991 Jun;7(3):139-46 [1878867.001]
  • [Cites] J Neurosurg Sci. 1991 Jan-Mar;35(1):55-7 [1890463.001]
  • [Cites] Zentralbl Neurochir. 1993;54(1):20-3 [8493835.001]
  • [Cites] Neurol Res. 1994 Apr;16(2):133-6 [7913998.001]
  • [Cites] Nervenarzt. 1996 Apr;67(4):301-5 [8684508.001]
  • [Cites] Clin Imaging. 1996 Apr-Jun;20(2):91-4 [8744815.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(6):678-83 [8836282.001]
  • [Cites] Childs Nerv Syst. 1997 Mar;13(3):154-65 [9137857.001]
  • [Cites] Surg Neurol. 1997 Jul;48(1):9-17; discussion 17-8 [9199678.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):190-7 [9254081.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 1996 Jun;25(3):135-8 [9275664.001]
  • [Cites] Neurol Med Chir (Tokyo). 1997 Dec;37(12):911-5 [9465590.001]
  • [Cites] Neurosurgery. 1998 Jun;42(6):1220-7; discussion 1227-8 [9632179.001]
  • [Cites] Neurochirurgie. 1997;43(5):303-7 [9686235.001]
  • [Cites] Ann Diagn Pathol. 1997 Oct;1(1):11-8 [9869821.001]
  • [Cites] Stroke. 1999 Mar;30(3):537-41 [10066848.001]
  • [Cites] No Shinkei Geka. 2000 Jan;28(1):67-72 [10642996.001]
  • (PMID = 16385664.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2810602
  •  go-up   go-down


36. Lin DW: Does RPLND improve outcomes in men with intermediate-risk and high-risk germ cell tumors? Nat Clin Pract Urol; 2007 Dec;4(12):654-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does RPLND improve outcomes in men with intermediate-risk and high-risk germ cell tumors?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] BJU Int. 2007 May;99(5):993-7 [17437432.001]
  • (PMID = 17971805.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Oldenburg J, Wahlqvist R, Fosså SD: Late relapse of germ cell tumors. World J Urol; 2009 Aug;27(4):493-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late relapse of germ cell tumors.
  • OBJECTIVE: To assess the main characteristics of late relapsing malignant germ cell tumors (MGCTs).
  • These tumors are rare and occur by definition 2 years or later after successful treatment.
  • Referral of late relapsing patients to high-volume institutions ensures the best chances of cure and enables multimodal treatment, and contributes to increased knowledge of tumor biology as well experience with the clinical course of these patients.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Neoplasms, Germ Cell and Embryonal / surgery. Retroperitoneal Neoplasms / surgery. Seminoma / surgery
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Teratoma / drug therapy. Teratoma / secondary. Teratoma / surgery. Testicular Neoplasms / drug therapy. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5503-11 [17158535.001]
  • [Cites] Eur Urol. 2008 Mar;53(3):478-96 [18191324.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Lancet. 2005 Jul 23-29;366(9482):293-300 [16039331.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5647-8 [18981457.001]
  • [Cites] BJU Int. 2003 Apr;91(6):469-73 [12656895.001]
  • [Cites] Lancet. 2005 Jul 23-29;366(9482):267-8 [16039313.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1235-40 [17665498.001]
  • [Cites] Eur Urol. 2008 Mar;53(3):497-513 [18191015.001]
  • [Cites] Eur Urol. 2005 Jan;47(1):64-71 [15582251.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1170-6 [7537800.001]
  • [Cites] J Urol. 1997 Mar;157(3):860-2 [9072586.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):358-62 [10637250.001]
  • [Cites] Ann Oncol. 1997 Jan;8(1):41-7 [9093706.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2781-8 [15837993.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4365-9 [17906201.001]
  • [Cites] Eur Urol. 2004 Jun;45(6):754-59; discussion 759-60 [15149748.001]
  • [Cites] J Urol. 2005 Mar;173(3):824-9 [15711278.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5603-8 [17998544.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1034-9 [15020605.001]
  • [Cites] Eur J Cancer. 1993;29A(14):1931-4 [8280484.001]
  • [Cites] Urology. 2009 Feb;73(2):328-31; discussion 331-2 [19022490.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5482-92 [17158533.001]
  • [Cites] Ann Oncol. 2008 Mar;19(3):443-7 [18048383.001]
  • [Cites] J Urol. 2002 Nov;168(5):1975-9 [12394688.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):820-7 [16508636.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):520-30 [12209744.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5524-9 [18936477.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):257-73 [10680894.001]
  • [Cites] Br J Urol. 1990 Jan;65(1):61-7 [1690070.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6549-55 [16170162.001]
  • [Cites] J Urol. 2009 Feb;181(2):627-32; discussion 632-3 [19091344.001]
  • [Cites] Can J Urol. 2005 Apr;12(2):2575-80 [15877938.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):113-22 [12506179.001]
  • [Cites] Eur Urol. 2009 Jan;55(1):217-24 [18926622.001]
  • [Cites] Eur J Cancer. 1995 Sep;31A(10):1599-604 [7488408.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1033-7 [17261854.001]
  • [Cites] Urology. 2004 Mar;63(3):550-5 [15028456.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2248-56 [17437287.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1146 [10561173.001]
  • [Cites] Br J Urol. 1993 Mar;71(3):326-35 [8386580.001]
  • [Cites] Urology. 2000 Jan;55(1):102-6 [10654903.001]
  • [Cites] J Natl Cancer Inst. 1999 May 19;91(10):839-46 [10340903.001]
  • [Cites] J Urol. 2007 Mar;177(3):937-42; discussion 942-3 [17296380.001]
  • [Cites] J Urol. 1995 Oct;154(4):1370-2 [7658541.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):863-9 [10970686.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Oct;5(5):869-74 [16221056.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4448-52 [12431967.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):324-9 [8381163.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5597-602 [18065732.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1101-6 [12637477.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):290-4 [9440755.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5416-21 [18936476.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17 ):3310-7 [12947067.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1668-76 [11920527.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Dec;64(3):182-97 [17644403.001]
  • [Cites] Can J Urol. 2002 Oct;9(5):1637-40 [12431325.001]
  • (PMID = 19373473.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 58
  •  go-up   go-down


38. Weikert S, Schrader M, Krause H, Schulze W, Müller M, Miller K: The inhibitor of apoptosis (IAP) survivin is expressed in human testicular germ cell tumors and normal testes. Cancer Lett; 2005 Jun 8;223(2):331-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The inhibitor of apoptosis (IAP) survivin is expressed in human testicular germ cell tumors and normal testes.
  • Deregulated apoptosis of germ cells may contribute to malignant transformation as well as male infertility.
  • We analyzed expression of the inhibitor of apoptosis survivin by polymerase chain reaction (PCR) in testicular germ cell tumors (TGCTs, n=28), normal testes (n=19) and testes with defective spermatogenesis (n=22).
  • While survivin mRNA was expressed at high levels in undifferentiated TGCTs and normal testes, it was lost in mature teratomas and germ cell aplasia.
  • Survivin expression in both normal and transformed germ cells is in contrast to its sharp differential expression in other tissues.
  • [MeSH-major] Cell Transformation, Neoplastic. Gene Expression Profiling. Microtubule-Associated Proteins / biosynthesis. Neoplasms, Germ Cell and Embryonal / genetics. Neoplasms, Germ Cell and Embryonal / physiopathology. Testicular Neoplasms / genetics. Testicular Neoplasms / physiopathology
  • [MeSH-minor] Humans. Infertility, Male. Inhibitor of Apoptosis Proteins. Male. Neoplasm Proteins. Reverse Transcriptase Polymerase Chain Reaction. Spermatogenesis

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896468.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


39. Gilbert DC, Chandler I, McIntyre A, Goddard NC, Gabe R, Huddart RA, Shipley J: Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents. J Pathol; 2009 Jan;217(1):94-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents.
  • Interaction between the chemokine CXCL12 (SDF1) and the G-protein coupled receptor CXCR4 is responsible for the maintenance of adult stem cell niches and is known to play an important role in utero in the migration of primordial germ cells.
  • We demonstrate expression of CXCL12 by Sertoli cells and confirm CXCR4 expression by the germ cell population of the adult human testes.
  • We identify consistent expression of CXCR4 mRNA and protein in testicular germ cell tumours (TGCT) that accounts for their patterns of relapse in sites of known CXCL12 expression.
  • Extragonadal primary germ cell tumours express CXCR4 and their sites of occurrence are coincident with areas of known CXCL12 expression in utero.
  • We show that CXCL12 stimulates the invasive migration of a TGCT cell line in vitro in a CXCR4-dependent fashion and activates ERK.
  • This may be through the loss of CXCL12 gradients that might otherwise attract cells away from the primary tumour.
  • Our observations support a role for CXCL12/CXCR4 in the adult germ cell population and demonstrate pathological function in germ cell tumour development and metastasis that may have clinical utility.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Chemokine CXCL12 / metabolism. Neoplasms, Germ Cell and Embryonal / metabolism. Receptors, CXCR4 / metabolism. Testicular Neoplasms / metabolism. Testis / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotaxis. Disease-Free Survival. Enzyme Activation. Humans. Male. Middle Aged. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Neoplasm Invasiveness. Neoplasm Proteins / metabolism. Prognosis. Recurrence. Reverse Transcriptase Polymerase Chain Reaction / methods. Tumor Cells, Cultured. Young Adult

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18839394.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U122861331
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL12 protein, human; 0 / CXCR4 protein, human; 0 / Chemokine CXCL12; 0 / Neoplasm Proteins; 0 / Receptors, CXCR4; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3
  •  go-up   go-down


40. Hoei-Hansen CE, Kraggerud SM, Abeler VM, Kaern J, Rajpert-De Meyts E, Lothe RA: Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers. Mol Cancer; 2007;6:12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ovarian germ cell tumours (OGCTs) typically arise in young females and their pathogenesis remains poorly understood.
  • We investigated the origin of malignant OGCTs and underlying molecular events in the development of the various histological subtypes of this neoplasia.
  • RESULTS: We examined in situ expression of stem cell-related (NANOG, OCT-3/4, KIT, AP-2gamma) and germ cell-specific proteins (MAGE-A4, NY-ESO-1, TSPY) using a tissue microarray consisting of 60 OGCT tissue samples and eight ovarian small cell carcinoma samples.
  • The molecular genetic part of our study included search for the presence of Y-chromosome material by fluorescence in situ hybridisation (FISH), and mutational analysis of the KIT oncogene (exon 17, codon 816), which is often mutated in testicular GCTs, in a subset of tumour DNA samples.
  • We detected a high expression of transcription factors related to the embryonic stem cell-like pluripotency and undifferentiated state in OGCTs, but not in small cell carcinomas, supporting the view that the latter do not arise from a germ cell progenitor.
  • Bilateral OGCTs expressed more stem cell markers than unilateral cases.
  • [MeSH-major] Biomarkers, Tumor / analysis. Dysgerminoma / pathology. Gene Expression Regulation, Neoplastic. Mutation. Ovarian Neoplasms / pathology. Pluripotent Stem Cells / pathology. Proto-Oncogene Proteins c-kit / genetics
  • [MeSH-minor] Antigens, Neoplasm / analysis. Carcinoma, Embryonal / chemistry. Carcinoma, Embryonal / genetics. Carcinoma, Embryonal / pathology. Carcinoma, Small Cell / chemistry. Carcinoma, Small Cell / genetics. Carcinoma, Small Cell / pathology. Cell Cycle Proteins / analysis. Cell Differentiation. Cell Lineage. Cell Transformation, Neoplastic / chemistry. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. DNA-Binding Proteins / analysis. Embryonal Carcinoma Stem Cells. Female. Gene Expression Regulation, Developmental. Gestational Age. Gonadoblastoma / chemistry. Gonadoblastoma / genetics. Gonadoblastoma / pathology. Homeodomain Proteins / analysis. Humans. Membrane Proteins / analysis. Neoplasm Proteins / analysis. Neoplastic Stem Cells / chemistry. Neoplastic Stem Cells / pathology. Octamer Transcription Factor-3 / analysis. Oogonia / chemistry. Oogonia / pathology. Ovary / chemistry. Ovary / embryology. Transcription Factor AP-2 / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Reprod. 2004 Jun;19(6):1338-44 [15105401.001]
  • [Cites] Hum Reprod Update. 2006 May-Jun;12(3):303-23 [16540528.001]
  • [Cites] J Pathol. 2004 Jul;203(3):849-57 [15221945.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4736-43 [15256440.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):537-44 [15349828.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1341-6 [15371950.001]
  • [Cites] Cancer Sci. 2004 Sep;95(9):716-20 [15471556.001]
  • [Cites] Int J Gynecol Pathol. 1988;7(4):315-29 [2852647.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(3):263-70 [1384223.001]
  • [Cites] Virchows Arch. 1994;424(2):135-41 [7514077.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3049-53 [7514496.001]
  • [Cites] Int J Androl. 1994 Apr;17(2):85-92 [7517917.001]
  • [Cites] Lab Invest. 1995 Feb;72(2):223-31 [7531795.001]
  • [Cites] Hum Mol Genet. 1996 Nov;5(11):1801-7 [8923009.001]
  • [Cites] Histopathology. 1997 Feb;30(2):177-86 [9190360.001]
  • [Cites] Immunol Today. 1997 Jun;18(6):267-8 [9190110.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3105-10 [9679978.001]
  • [Cites] Am J Med Genet. 1999 May 7;84(1):43-6 [10213045.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1643-7 [10362788.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Oct;84(10):3836-44 [10523039.001]
  • [Cites] Cancer. 1953 May;6(3):455-63 [13042769.001]
  • [Cites] Biol Reprod. 2004 Dec;71(6):2012-21 [15317684.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):651-4 [15455230.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):254-5 [15589612.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3025-30 [10850452.001]
  • [Cites] Cytogenet Cell Genet. 2000;91(1-4):160-4 [11173850.001]
  • [Cites] Mol Hum Reprod. 2001 Sep;7(9):845-52 [11517291.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2778-85 [11753951.001]
  • [Cites] Lab Invest. 2002 Jun;82(6):775-80 [12065688.001]
  • [Cites] Lab Invest. 2002 Oct;82(10):1369-75 [12379771.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Feb;18(2):147-51 [12542597.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2244-50 [12727846.001]
  • [Cites] APMIS. 2003 Jan;111(1):43-6; discussion 46-8 [12752232.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7674-8 [14633689.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):305-13 [14695343.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6453-60 [14695148.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8521-30 [15623634.001]
  • [Cites] Int J Cancer. 2005 Jun 20;115(3):470-7 [15700319.001]
  • [Cites] Mol Cell Endocrinol. 2005 Apr 29;234(1-2):1-10 [15836947.001]
  • [Cites] Gene Expr Patterns. 2005 Jun;5(5):639-46 [15939376.001]
  • [Cites] Histopathology. 2005 Jul;47(1):48-56 [15982323.001]
  • [Cites] J Reprod Med. 2005 Jun;50(6):417-25 [16050566.001]
  • [Cites] Virchows Arch. 2005 Sep;447(3):603-9 [15968543.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):289-96 [16188233.001]
  • [Cites] Mod Pathol. 2005 Nov;18(11):1411-6 [16056250.001]
  • [Cites] Gynecol Oncol. 2006 Mar;100(3):462-8 [16216317.001]
  • [Cites] J Neurosurg. 2006 Mar;104(3 Suppl):173-80 [16572634.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2397-401 [15150569.001]
  • (PMID = 17274819.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CTAG1B protein, human; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / MAGEA4 protein, human; 0 / Membrane Proteins; 0 / NANOG protein, human; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human; 0 / TFAP2C protein, human; 0 / TSPY1 protein, human; 0 / Transcription Factor AP-2; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC1797189
  •  go-up   go-down


41. McIntyre A, Summersgill B, Grygalewicz B, Gillis AJ, Stoop J, van Gurp RJ, Dennis N, Fisher C, Huddart R, Cooper C, Clark J, Oosterhuis JW, Looijenga LH, Shipley J: Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res; 2005 Sep 15;65(18):8085-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults.
  • We have previously identified amplification at 4q12 in testicular germ cell tumors of adolescents and adults centered around the KIT gene encoding a tyrosine kinase transmembrane receptor.
  • Analysis of primary testicular germ cell tumors totaling 190 cases revealed 21% of the seminoma subtype with an increased copy number of KIT whereas this change was rarely found in the nonseminomas.
  • Increased copy number of KIT was not found in the putative precursor lesion, carcinoma in situ (CIS), adjacent to tumor with this change.
  • [MeSH-major] Proto-Oncogene Proteins c-kit / genetics. Seminoma / genetics. Seminoma / pathology. Testicular Neoplasms / genetics. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166280.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


42. Galani E, Alamanis C, Dimopoulos MA: Familial female and male germ cell cancer. A new syndrome? Gynecol Oncol; 2005 Jan;96(1):254-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial female and male germ cell cancer. A new syndrome?
  • BACKGROUND: A small percentage of germ cell tumors is known to be familial.
  • There are several reports describing familial cases of testicular germ cell tumors; however, there are only a few of them reporting germ cell tumors that occurred in both males and females of the same family.
  • CASE: We present a family with three children, two females and one male, previously healthy, who all developed germ cell malignancies.
  • CONCLUSION: Our case report suggests that the possibility of an association between germ cell tumors of both ovaries and testis should be considered.
  • [MeSH-major] Ovarian Neoplasms / genetics. Teratoma / genetics. Testicular Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589612.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Korkola JE, Houldsworth J, Dobrzynski D, Olshen AB, Reuter VE, Bosl GJ, Chaganti RS: Gene expression-based classification of nonseminomatous male germ cell tumors. Oncogene; 2005 Jul 28;24(32):5101-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression-based classification of nonseminomatous male germ cell tumors.
  • Male adult germ cell tumors (GCTs) comprise two major histologic groups: seminomas and nonseminomas.
  • Nonseminomatous GCTs (NSGCTs) can be further divided into embryonal carcinoma (EC), teratoma (T), yolk sac tumor (YS), and choriocarcinoma (CC) on the basis of the lineage differentiation that they exhibit.
  • NSGCTs frequently present as mixed tumors consisting of two or more histological subtypes, often limiting correlative studies of clinical and molecular features to histology.
  • We sought to develop a molecular classifier that could predict the predominant histologic subtype within mixed NSGCT tumor samples.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genital Neoplasms, Male / genetics
  • [MeSH-minor] Humans. Male. Reverse Transcriptase Polymerase Chain Reaction. Seminoma / genetics. Teratoma / genetics. Testicular Neoplasms / genetics. Transcription, Genetic


44. Shinagare AB, Jagannathan JP, Ramaiya NH, Hall MN, Van den Abbeele AD: Adult extragonadal germ cell tumors. AJR Am J Roentgenol; 2010 Oct;195(4):W274-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult extragonadal germ cell tumors.
  • OBJECTIVE: The purpose of this article is to describe the key imaging features of primary and metastatic extragonadal germ cell tumors in adults.
  • CONCLUSION: Extragonadal germ cell tumors primarily affect men during the third and fourth decades of life.
  • Their imaging characteristics are nonspecific, and extragonadal germ cell tumors should always be included in the differential diagnosis of a midline anterior mediastinal or retroperitoneal mass.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Male. Mediastinal Neoplasms / diagnosis. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20858789.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Feldman DR, Bosl GJ: Curing germ cell tumors after failure of high-dose chemotherapy: progress through clinical trials. Nat Clin Pract Oncol; 2007 Sep;4(9):508-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curing germ cell tumors after failure of high-dose chemotherapy: progress through clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2007 Feb 10;25(5):513-6 [17290059.001]
  • (PMID = 17637730.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  •  go-up   go-down


46. De Backer A, Madern GC, Wolffenbuttel KP, Oosterhuis JW, Hakvoort-Cammel FG, Hazebroek FW: Testicular germ cell tumors in children: management and outcome in a series of 20 patients. J Pediatr Urol; 2006 Jun;2(3):197-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular germ cell tumors in children: management and outcome in a series of 20 patients.
  • Testicular germ cell tumors occurring during childhood are extremely rare.
  • This study reports the clinical presentation, pathological diagnosis, treatment methods and outcome in a series of 20 boys, aged between 3.5 months and 16 years (median: 1.5 years; 19 were prepubertal), who were treated between 1963 and 2003.
  • Histologically, mature teratoma was present in seven, immature teratoma in four and yolk sac tumor in nine.
  • Of the 11 teratomas, 10 were treated by orchiectomy and one by testis-sparing tumor excision only.
  • The nine patients with yolk sac tumor were managed by orchiectomy, in two plus retroperitoneal lymphadenectomy, and in eight plus chemotherapy.
  • One patient is in remission for 10 months, seven are alive with no evidence of disease for 5.5-23 years, and one patient died from a T-cell acute lymphoblastic leukemia, 2 years after the end of treatment of the testicular tumor.
  • This study confirms the excellent cure rates obtained in children with testicular germ cell tumor, provided diagnosis is prompt and treatment accurate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18947609.001).
  • [ISSN] 1873-4898
  • [Journal-full-title] Journal of pediatric urology
  • [ISO-abbreviation] J Pediatr Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


47. Tanaka K, Hara I, Takenaka A, Kawabata G, Fujisawa M: Incidence of local and port site recurrence of urologic cancer after laparoscopic surgery. Urology; 2008 Apr;71(4):728-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No patients without a histologic diagnosis of cancer were included in this study.
  • The histologic type of both testicular cancers was mixed germ cell tumor, with one occurring in a renal hilar lymph node and the other in a paraaortic lymph node and kidney.
  • The histologic type of the renal cell carcinoma was papillary renal cell carcinoma with sarcomatoid features (Stage pT3aN1), and it occurred in a retrocaval lymph node.
  • The histologic type of the bladder cancer was transitional cell carcinoma, Grade 3, Stage pT4aN0, and it presented as peritoneal carcinomatosis 11 months postoperatively.
  • [MeSH-major] Laparoscopy / adverse effects. Neoplasm Recurrence, Local / epidemiology. Neoplasm Seeding. Urologic Neoplasms / pathology. Urologic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18279936.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Lim ST, Levine AM: Non-AIDS-Defining Cancers and HIV Infection. Curr Infect Dis Rep; 2005 May;7(3):227-234
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These include Hodgkin's disease, anal carcinoma, lung cancer, nonmelanomatous skin cancer, and testicular germ cell tumors, among others.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Eur J Epidemiol. 1995 Dec;11(6):609-14 [8861842.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):367-71 [12607641.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):444-50 [11035615.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Apr;5(2):343-56 [2022598.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1602-8 [9362158.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] AIDS Care. 1996 Feb;8(1):5-14 [8664369.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):635-41 [8240994.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2540-6 [7595705.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2705-11 [7595728.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2739-45 [11753946.001]
  • [Cites] Int J STD AIDS. 2001 Feb;12(2):100-2 [11236097.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):432-6 [1617592.001]
  • [Cites] Cancer. 1990 May 15;65(10):2248-54 [2346909.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):189-95 [10093688.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):563-9 [10649248.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1391-7 [7538557.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1348-9; author reply 1349-50 [15051794.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):292-8 [12856222.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):480-8 [10950375.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):997-1010 [8880192.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] Chest. 1993 Feb;103(2):410-3 [8432128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Sep;11(9):1587-93 [3928544.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12667-71 [11058153.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Chest. 1998 Jan;113(1):154-61 [9440583.001]
  • [Cites] Mutat Res. 1999 Oct 19;429(2):249-59 [10526209.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1922-7 [12743144.001]
  • [Cites] Fundam Appl Toxicol. 1996 Aug;32(2):148-58 [8921318.001]
  • [Cites] Mutagenesis. 2000 Sep;15(5):405-10 [10970446.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:201-5 [1710920.001]
  • [Cites] Lung Cancer. 2002 Apr;36(1):9-14 [11891027.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):457-9 [12888811.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1520-4 [8944046.001]
  • [Cites] Chest. 1992 Dec;102(6):1704-8 [1446476.001]
  • (PMID = 15847726.001).
  • [ISSN] 1523-3847
  • [Journal-full-title] Current infectious disease reports
  • [ISO-abbreviation] Curr Infect Dis Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Pentheroudakis G, Mauri D, Kostadima L, Golfinopoulos V, Alexiou G, Karakatsanis A, Pavlidis N: "Juvenile" oncology--a missing subspecialty. The experience of a reference cancer centre. Clin Transl Oncol; 2006 Jun;8(6):444-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Juvenile" oncology--a missing subspecialty. The experience of a reference cancer centre.
  • INTRODUCTION: Despite unique tumor epidemiology and a higher cancer incidence compared to pediatric patients, adolescents and young adults have not been receiving specialized, multidisciplinary, centralized care.
  • METHODS: Cohort of 150 patients aged 15-30 treated for malignant tumors of lymphoid and solid organs from 1986 to 2002.
  • RESULTS: Patients aged 15-19 commonly had lymphomas, germ cell tumors and pediatric sarcomas, whereas those aged 20-30 experienced germ cell tumors, lymphomas, melanomas and epithelial tumors more often.
  • [MeSH-major] Cancer Care Facilities / statistics & numerical data. Medical Oncology. Neoplasms / epidemiology. Pediatrics
  • [MeSH-minor] Academic Medical Centers / statistics & numerical data. Adolescent. Adult. Antineoplastic Agents / adverse effects. Diagnosis-Related Groups. Female. Greece / epidemiology. Hospitals, University / statistics & numerical data. Humans. Incidence. Interdisciplinary Communication. Male. Patient Care Team. Postoperative Complications / epidemiology. Quality of Life. Radiotherapy / adverse effects. Referral and Consultation. Retrospective Studies. Social Support. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Children's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2002 Nov 18;87(11):1267-74 [12439716.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 May;21(5):601-5 [2408897.001]
  • [Cites] Cancer. 1993 May 15;71(10 Suppl):3441-9 [8490895.001]
  • [Cites] Med Pediatr Oncol. 1995 Sep;25(3):159-65 [7623724.001]
  • [Cites] Cancer. 1993 May 15;71(10 Suppl):3206-9 [8490852.001]
  • [Cites] Br Med Bull. 1996 Oct;52(4):887-97 [9039738.001]
  • [Cites] Med Pediatr Oncol. 2002 Jan;38(1):1-10 [11835231.001]
  • [Cites] Clin Radiol. 1989 Mar;40(2):204-8 [2647360.001]
  • [Cites] Ann Intern Med. 1996 Jul 1;125(1):47-58 [8644988.001]
  • [Cites] J Adolesc Health. 1997 Dec;21(6):366-73 [9401854.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):774-80 [12610173.001]
  • [Cites] Pediatr Nurs. 1995 May-Jun;21(3):235-40 [7792105.001]
  • [Cites] Int J Cancer. 1995 Jan 27;60(3):355-60 [7829244.001]
  • (PMID = 16790398.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


50. Pectasides D, Pectasides E, Constantinidou A, Aravantinos G: Stage I testicular seminoma: management and controversies. Crit Rev Oncol Hematol; 2009 Jul;71(1):22-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seminomas constitute more than half of testicular germ-cell tumours and 70-80% of patients with seminoma present with clinical stage I disease.
  • [MeSH-major] Seminoma / therapy. Testicular Neoplasms / therapy

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046898.001).
  • [ISSN] 1879-0461
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 65
  •  go-up   go-down


51. Newsom-Davis T, Poulter D, Gray R, Ameen M, Lindsay I, Papanikolaou K, Butler-Manuel S, Christmas T, Townsend P, Seckl M: Case report: malignant teratoma of the uterine corpus. BMC Cancer; 2009;9:195
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Teratomas are the commonest germ cell tumours and are most frequently found in the testes and ovary.
  • CONCLUSION: In this report we discuss the aetiology, diagnosis and management of uterine teratomas, and review previous case studies.
  • [MeSH-major] Teratoma / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Hysterectomy. Lymphatic Diseases / etiology. Lymphatic Metastasis. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2003 May;53(5):327-31 [12713570.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1169-75 [15026797.001]
  • [Cites] Obstet Gynecol. 1972 Nov;40(5):686-91 [5083218.001]
  • [Cites] N Engl J Med. 1975 Jan 9;292(2):63-6 [162806.001]
  • [Cites] Histopathology. 1979 Jul;3(4):339-45 [468134.001]
  • [Cites] Gynecol Oncol. 1985 May;21(1):106-10 [3988122.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1578-83 [18453518.001]
  • [Cites] Acta Obstet Gynecol Scand. 1998 Oct;77(9):936-8 [9808385.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):216-8 [15972426.001]
  • [Cites] Ultrasound Obstet Gynecol. 2007 Apr;29(4):477-8 [17330830.001]
  • [Cites] Ann Diagn Pathol. 2007 Aug;11(4):293-6 [17630116.001]
  • [Cites] Obstet Gynecol. 2007 Aug;110(2 Pt 2):491-3 [17666639.001]
  • [Cites] Int J Gynecol Cancer. 2008 Jan-Feb;18(1):43-50 [17466047.001]
  • [Cites] Kurume Med J. 1993;40(3):153-8 [8139215.001]
  • (PMID = 19538751.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2709639
  •  go-up   go-down


52. Casey RG, Aktar M, Hegarty P, Butler M, Thornhill JA: A prospective 10 year audit of a single Irish centre's experience of retroperitoneal lymph node dissection for metastatic testis cancer. Surgeon; 2008 Oct;6(5):294-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective 10 year audit of a single Irish centre's experience of retroperitoneal lymph node dissection for metastatic testis cancer.
  • BACKGROUND: Retro-peritoneal lymph node dissection (RPLND) following chemotherapy is critical in advanced germ cell tumours with residual retro-peritoneal masses.
  • CONCLUSIONS: The decision to perform post-chemotherapy RPLND depends on the possibility of viable tumour or teratoma and surgical morbidity.
  • [MeSH-major] Lymph Node Excision. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Humans. Ireland. Length of Stay / statistics & numerical data. Lymphatic Metastasis / pathology. Male. Medical Audit. Middle Aged. Neoplasm Staging. Prospective Studies. Retroperitoneal Space / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18939377.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


53. Ong TA, Winkler MH, Savage PM, Seckl MJ, Christmas TJ: Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome. BJU Int; 2008 Jul;102(2):198-202
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome.
  • OBJECTIVE: To evaluate the factors affecting outcome and the pathological findings in patients who had retroperitoneal lymph node dissection (pcRPLND) after chemotherapy with elevated tumour markers, as such patients have an unfavourable prognosis, with further salvage chemotherapy being the usual treatment of choice.
  • PATIENTS AND METHODS: Information on the preoperative treatment, tumour markers, histopathology and outcome data of the patients who had pcRPLND were extracted from the hospital databases.
  • In 48 patients the tumour markers were elevated at the time of surgery, they were on a 'rising trend' in 26 (54%) and 'downward or stable' trend in 22 (46%).
  • The overall incidence of active germ cell tumour, differentiated teratoma and necrosis in the resected specimens was 58%, 25% and 17%, respectively.
  • The favourable prognostic factors assessed by univariate analysis were elevation of alpha-fetoprotein alone, complete resection of residual disease, histological finding of differentiated teratoma in the resected tissues and normalization of tumour markers after pcRPLND.
  • By multivariate analysis the only statistically significant independent survival factor was the normalization of the tumour markers after pcRPLND.
  • CONCLUSION: For selected patients with elevated tumour markers after chemotherapy, RPLND can offer a significant chance of cure with no need for further chemotherapy.
  • [MeSH-major] Chorionic Gonadotropin, beta Subunit, Human / metabolism. Lymph Node Excision / methods. Neoplasms, Germ Cell and Embryonal / therapy. Salvage Therapy / methods. Testicular Neoplasms / therapy. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294302.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


54. Islam S, Yamout SZ, Gosche JR: Management and outcomes of ovarian masses in children and adolescents. Am Surg; 2008 Nov;74(11):1062-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Demographic and tumor-specific data were reviewed and analyzed, and a Student's unpaired t test was used where appropriate.
  • Eight masses were malignant (16%) with malignant teratoma, dysgerminoma, and germ cell tumors found.
  • Seventy-four per cent of the benign tumors were teratomas.
  • [MeSH-major] Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19062661.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Stremmel C, Passlick B: [Surgery of mediastinal tumors]. Chirurg; 2008 Jan;79(1):9-10, 12-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgery of mediastinal tumors].
  • Thymomas, lymphomas, and germ cell tumors are the most frequent lesions of the anterior mediastinum, whereas endodermal (bronchogenic) cysts and lymphomas are the most frequent lesions of the middle mediastinum.
  • In the posterior mediastinum, neurogenic tumors and soft-tissue sarcomas are the most frequent.
  • Depending on tumor location, mediastinoscopy, mediastinotomy, and thoracoscopy are the preferred diagnostic methods.
  • Thoracoscopy should be performed only in patients with myasthenia gravis and with very small tumors.
  • Surgical treatment is highly recommended in patients with locally recurrent tumors.
  • The importance of surgical treatment of germ cell tumors is determined by a negative concentration of beta-HCG and alpha-fetoprotein and in cases of residual tumor after chemotherapy.
  • Ninety-eight percent of neurogenic tumors in adults are benign and usually resected via thoracoscopy or thoracotomy, depending on location and size.
  • [MeSH-major] Lymphoma / surgery. Mediastinal Neoplasms / surgery. Neoplasms, Germ Cell and Embryonal / surgery. Thymoma / surgery. Thymus Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Child. Female. Humans. Incidence. Male. Mediastinoscopy. Mediastinum / pathology. Neoplasm Staging. Prognosis. Radiography. Thoracoscopy. Thoracotomy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 1991 Jul;52(1):6-13 [2069465.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Aug;112(2):376-84 [8751506.001]
  • [Cites] J Thorac Cardiovasc Surg. 1983 Nov;86(5):727-31 [6632945.001]
  • [Cites] Chest. 1991 Feb;99(2):472-9 [1846573.001]
  • [Cites] Ann Thorac Surg. 1966 Jul;2(4):532-9 [5934068.001]
  • [Cites] J Pediatr Surg. 1986 Jun;21(6):548-51 [2425069.001]
  • [Cites] Cancer. 1981 Jan 15;47(2):373-81 [7459826.001]
  • [Cites] Ann Thorac Surg. 2003 Sep;76(3):878-84; discussion 884-5 [12963221.001]
  • [Cites] Ann Thorac Surg. 2002 Aug;74(2):615-23 [12173869.001]
  • [Cites] Ann Thorac Surg. 1986 Sep;42(3):338-45 [3530162.001]
  • [Cites] Ann Surg. 1948 Mar;127(3):476-502 [17859095.001]
  • [Cites] Ann Thorac Surg. 1991 Jan;51(1):152-6 [1985561.001]
  • [Cites] Ann Thorac Surg. 1987 Sep;44(3):229-37 [2820323.001]
  • [Cites] Int J Cancer. 2003 Jul 1;105(4):546-51 [12712448.001]
  • [Cites] Ann Thorac Surg. 2001 Jul;72 (1):208-11 [11465181.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1864-73 [11919246.001]
  • [Cites] Surg Today. 2005;35(10):805-11 [16175459.001]
  • [Cites] J Surg Oncol. 1992 May;50(1):43-6 [1573893.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Feb;125(2):434-6 [12579125.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):103-10 [11145244.001]
  • [Cites] Ann Thorac Surg. 2003 Dec;76(6):1859-64; discussion 1864-5 [14667600.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1979 Jul 27;383(1):43-57 [157612.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):681-90 [9264351.001]
  • [Cites] Ann Thorac Surg. 1995 Oct;60(4):943-6 [7574999.001]
  • [Cites] Thorax. 1978 Jun;33(3):359-67 [210531.001]
  • [Cites] Cancer. 1992 Jun 1;69(11):2755-60 [1373989.001]
  • [Cites] Ann Thorac Surg. 1995 Oct;60(4):908-13; discussion 914 [7574993.001]
  • [Cites] Ann Thorac Surg. 2004 May;77(5):1860-9 [15111216.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):562-72; discussion 572-4 [10522726.001]
  • (PMID = 18058077.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 31
  •  go-up   go-down


56. Shrivastava CP, Devgarha S, Ahlawat V: Mediastinal tumors: a clinicopathological analysis. Asian Cardiovasc Thorac Ann; 2006 Apr;14(2):102-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal tumors: a clinicopathological analysis.
  • Between January 1993 and June 2003, 106 patients underwent surgical treatment of a mediastinal mass.
  • Histopathologically, 41 (39%) patients had thymic pathology, 31 (29%) had lymphoma, 14 (13%) had germ cell tumors, 12 (11%) had neurofibroma, 4 (4%) had ganglioneuroma, 2 (2%) had bronchogenic cyst, and 1 each had thymic cyst and mesothelioma.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551814.001).
  • [ISSN] 1816-5370
  • [Journal-full-title] Asian cardiovascular & thoracic annals
  • [ISO-abbreviation] Asian Cardiovasc Thorac Ann
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Koulouris CR, Penson RT: Ovarian stromal and germ cell tumors. Semin Oncol; 2009 Apr;36(2):126-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian stromal and germ cell tumors.
  • Cancers arising from the stromal and germ cell layers of the ovary are rare, heterogeneous, difficult to study, and require specialized multidisciplinary management.
  • These tumors more commonly present in younger patients and have a high cure rate.
  • They are associated with serum markers that are informative for diagnosis and surveillance.
  • Most patients with germ cell tumors require adjuvant chemotherapy with bleomycin, etoposide, and cisplatin (BEP), as well as careful surveillance.
  • The rarity of these tumors makes basic scientific advances more challenging.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal. Ovarian Neoplasms. Sex Cord-Gonadal Stromal Tumors
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19332247.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 78
  •  go-up   go-down


58. Palmer RD, Murray MJ, Saini HK, van Dongen S, Abreu-Goodger C, Muralidhar B, Pett MR, Thornton CM, Nicholson JC, Enright AJ, Coleman N, Children's Cancer and Leukaemia Group: Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. Cancer Res; 2010 Apr 01;70(7):2911-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets.
  • Despite their extensive clinical and pathologic heterogeneity, all malignant germ cell tumors (GCT) are thought to originate from primordial germ cells.
  • We profiled 615 microRNAs (miRNA) in pediatric malignant GCTs, controls, and GCT cell lines (48 samples in total) and re-analyzed available miRNA expression data in adult gonadal malignant GCTs.
  • The most significant differentially expressed miRNAs in malignant GCTs were all from the miR-371-373 and miR-302 clusters (adjusted P < 0.00005), which were overexpressed regardless of histologic subtype [yolk sac tumor (YST)/seminoma/embryonal carcinoma (EC)], site (gonadal/extragonadal), or patient age (pediatric/adult).
  • [MeSH-major] MicroRNAs / biosynthesis. Neoplasms, Germ Cell and Embryonal / genetics. RNA, Messenger / biosynthesis
  • [MeSH-minor] Adult. Child. Cluster Analysis. Down-Regulation. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Male. Oligonucleotide Array Sequence Analysis. Seminoma / genetics. Seminoma / metabolism. Testicular Neoplasms / genetics. Testicular Neoplasms / metabolism. Transcription, Genetic

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2006 Mar 24;124(6):1169-81 [16564011.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6188-96 [17028598.001]
  • [Cites] Acta Neuropathol. 2009 Apr;117(4):457-64 [19057917.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Methods. 2003 Dec;31(4):265-73 [14597310.001]
  • [Cites] Nature. 2005 Feb 17;433(7027):769-73 [15685193.001]
  • [Cites] Cell. 2003 Dec 26;115(7):787-98 [14697198.001]
  • [Cites] J Pathol. 2008 May;215(1):21-30 [18348160.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Mol Cancer. 2007;6:60 [17894887.001]
  • [Cites] Mol Cell Biol. 2008 Nov;28(21):6609-19 [18725401.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):820-7 [16424014.001]
  • [Cites] J Pathol. 2009 Jun;218(2):146-62 [19253916.001]
  • [Cites] Nat Genet. 2008 Dec;40(12):1478-83 [18978791.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):307-15 [14960456.001]
  • [Cites] Dev Biol. 2004 Jun 15;270(2):488-98 [15183728.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4239-47 [18519683.001]
  • [Cites] Bioinformatics. 2005 May 1;21(9):2067-75 [15657102.001]
  • [Cites] J Pathol. 2007 Jul;212(3):325-34 [17516585.001]
  • [Cites] Genes Dev. 2006 Aug 15;20(16):2202-7 [16882971.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Stat Appl Genet Mol Biol. 2004;3:Article3 [16646809.001]
  • [Cites] Nat Methods. 2009 Jun;6(6):397-8 [19478799.001]
  • [Cites] Cell. 2008 Aug 8;134(3):521-33 [18692474.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8012-7 [11416159.001]
  • [Cites] Nat Methods. 2008 Dec;5(12):1023-5 [18978784.001]
  • [Cites] Am J Clin Pathol. 2009 May;131(5):731-6 [19369635.001]
  • [Cites] Bioinformatics. 2009 Feb 1;25(3):415-6 [19106121.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] J Cell Mol Med. 2008 Dec;12(6A):2181-8 [19120702.001]
  • [Cites] Dev Biol. 2007 Feb 1;302(1):1-12 [16989803.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D154-8 [17991681.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64(4):407-29 [5318716.001]
  • [Cites] Stem Cells Dev. 2007 Dec;16(6):1003-16 [18004940.001]
  • [Cites] Science. 2006 Apr 7;312(5770):75-9 [16484454.001]
  • [Cites] J Pathol. 2007 Nov;213(3):319-28 [17893849.001]
  • [Cites] J Pathol. 2007 Aug;212(4):368-77 [17471471.001]
  • [Cites] Bioinformatics. 2007 Jan 15;23(2):257-8 [17098774.001]
  • [Cites] Mol Cell Biol. 2008 Oct;28(20):6426-38 [18710938.001]
  • [Cites] Cell. 2009 May 15;137(4):647-58 [19409607.001]
  • [Cites] Genome Res. 2004 Jan;14(1):179-87 [14672980.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4093-6 [19435891.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • (PMID = 20332240.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105359875; United Kingdom / Medical Research Council / / ; United Kingdom / Medical Research Council / / U.1053.00.002(59875); United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / / G9900837; United Kingdom / Medical Research Council / / G0700089; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC3000593; NLM/ UKMS28624
  •  go-up   go-down


59. Zhou JF, Bai CM, Yang D, Chen SC: [Clinical analysis of primary mediastinal germ cell tumors]. Zhonghua Zhong Liu Za Zhi; 2007 Jul;29(7):531-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of primary mediastinal germ cell tumors].
  • OBJECTIVE: To investigate the clinical and pathological features, optimal treatment and prognostic factor in primary mediastinal germ cell tumors (PMGCT).
  • RESULTS: All the 29 patients were male with a mean age of 26.1 +/- 9.6 years at diagnosis.
  • All tumors were originated from the anterior mediastinum with a mean diameter of 16.0 +/- 5.2 cm.
  • Cox multivariate analysis indicated that limited mediastinal disease at diagnosis (P = 0.004) and the use of cisplatin-based combined chemotherapy (P = 0.005) were independent good prognostic factors of PMNSGCT.
  • CONCLUSION: Primary mediastinal nonseminoma constitutes the most of primary mediastinal germ cell tumors.
  • Cisplatin-based combined chemotherapy may be the most effective for the treatment of primary mediastinal germ cell tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mediastinal Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / therapy. Seminoma / therapy

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18069635.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Taxoids; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; BEP protocol; TIP regimen
  •  go-up   go-down


60. Guerrero-Vázquez S, Armesto-Pérez V, Macía-Suárez D, Branas-Fernández FM: [Simultaneous suprasellar and pineal germinoma: a case report]. Rev Neurol; 2008 Apr 1-15;46(7):411-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Germinoma pineal y supraselar sincrónico: a propósito de un caso.
  • INTRODUCTION: Tumours in the pineal region are rare (0.3-2.7%) and most of the ones that do occur are germ cell tumours, of which germinoma is the most frequent.
  • The main aim of this study is to review the differential diagnosis of neoplasias in the pineal region.
  • CASE REPORT: Here we report the case of a 20-year-old male who was admitted to hospital due to irregularities affecting the field of vision, with clinical signs and symptoms of panhypopituitarism and normal levels of tumour markers in blood and cerebrospinal fluid.
  • CONCLUSIONS: Magnetic resonance imaging plays a decisive role in establishing the diagnosis and therapy plan.
  • The patient's medical record (age, sex or tumour markers) must also be taken into consideration.
  • [MeSH-major] Brain Neoplasms / diagnosis. Germinoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pineal Gland
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Pituitary Gland

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18389460.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


61. Beck SD: Management options for stage 1 nonseminomatous germ cell tumors of the testis. Indian J Urol; 2010 Jan-Mar;26(1):72-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management options for stage 1 nonseminomatous germ cell tumors of the testis.
  • Management of clinical stage I non seminomatous germ cell tumor includes surveillance, primary chemotherapy and retroperitoneal lymph node dissection.
  • Stratifying clinical stage I disease to high-and low-risk groups for harboring micrometastic retroperitoneal disease (pathologic stage B) is based on pathologic characteristics of the primary tumor.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2004 Mar;63(3):550-5 [15028456.001]
  • [Cites] Urol Clin North Am. 1990 May;17(2):449-56 [2336749.001]
  • [Cites] J Natl Cancer Inst. 2009 Dec 16;101(24):1682-95 [19940282.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4327-32 [19652075.001]
  • [Cites] World J Urol. 2009 Aug;27(4):455-61 [19636566.001]
  • [Cites] World J Urol. 2009 Aug;27(4):441-7 [19609532.001]
  • [Cites] J Urol. 2008 Oct;180(4):1348-52; discussion 1352-3 [18707723.001]
  • [Cites] J Urol. 2007 Aug;178(2):504-6; discussion 506 [17561131.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1310-5 [17416851.001]
  • [Cites] Eur Urol. 2007 Jan;51(1):34-43; discussion 43-4 [16996677.001]
  • [Cites] J Urol. 2006 Oct;176(4 Pt 1):1424-29; discussion 1429-30 [16952649.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 1):1287-90; discussion 1290 [16145394.001]
  • [Cites] J Urol. 2005 Jul;174(1):143-5 [15947600.001]
  • [Cites] Can J Urol. 2005 Apr;12(2):2575-80 [15877938.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2700-4 [7595727.001]
  • [Cites] World J Urol. 1994;12(3):136-8 [7951339.001]
  • [Cites] J Urol. 1994 Aug;152(2 Pt 1):424-7 [8015086.001]
  • [Cites] Urology. 2003 Aug;62(2):324-7 [12893344.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1505-12 [12697874.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):2020-5 [11283135.001]
  • [Cites] Eur J Cancer. 2000 Mar;36(4):472-5 [10717522.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):358-62 [10637250.001]
  • [Cites] J Urol. 1993 Feb;149(2):237-43 [8381190.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1762-8 [1403057.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1393-6 [2072143.001]
  • [Cites] Int J Androl. 1987 Feb;10(1):277-84 [2438221.001]
  • [Cites] N Engl J Med. 1987 Dec 3;317(23):1433-8 [2446132.001]
  • [Cites] Lancet. 1987 Aug 8;2(8554):294-8 [2886764.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4092-9 [14559885.001]
  • (PMID = 20535290.001).
  • [ISSN] 1998-3824
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2878443
  • [Keywords] NOTNLM ; Retroperitoneal lymph node dissection / stage 1 / testis cancer
  •  go-up   go-down


62. Corvin S, Sturm W, Kuczyk M, Anastasiadis AG, Stenzl A: Laparoscopic retroperitoneal lymphadenectomy in the management of low-stage testicular cancer: technique and results. Minim Invasive Ther Allied Technol; 2005;14(2):52-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In conclusion, laparoscopic RPLND is a safe method for the management of low-stage germ cell tumors with minimal invasiveness and excellent clinical results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16754617.001).
  • [ISSN] 1364-5706
  • [Journal-full-title] Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  • [ISO-abbreviation] Minim Invasive Ther Allied Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


63. Walsh TJ, Davies BJ, Croughan MS, Carroll PR, Turek PJ: Racial differences among boys with testicular germ cell tumors in the United States. J Urol; 2008 May;179(5):1961-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Racial differences among boys with testicular germ cell tumors in the United States.
  • PURPOSE: There are marked racial differences in the incidence of testicular germ cell tumors among United States men, with whites having 5 times the incidence of blacks and 3 times that of Asians.
  • Testicular germ cell tumors in boys are rare, and limited racial classification by cancer registries has made attempts to discern racial patterns difficult.
  • We hypothesize that recent diversification of race data by cancer registries may allow for more accurate racial classification, and that there are racial differences in the incidence of testicular germ cell tumors in prepubertal boys.
  • MATERIALS AND METHODS: We identified all cases of histologically confirmed testicular germ cell cancer in boys 0 to 14 years old between 1992 and 2004 through the Surveillance, Epidemiology and End Results Program.
  • Variables analyzed included age, tumor histology and year of diagnosis.
  • RESULTS: A total of 695 cases of testicular germ cell tumors were diagnosed among boys of all races, with an overall incidence of 6.3 per 1 million person-years.
  • Testicular germ cell tumors were 1.4-fold more likely to develop in Asian/Pacific Islanders compared to whites (RR 1.4, 95% CI 1.1 to 1.8).
  • Increased rates among Asian/Pacific Islanders were constant across all age strata, in cases of yolk sac tumor/embryonal, teratoma and seminoma, and were maintained from 1992 to 2004.
  • CONCLUSIONS: Asian/Pacific Islander boys are more likely to have testicular germ cell tumors compared to whites.
  • Similar to adults, race appears to have a significant role in the incidence of testicular germ cell tumors among prepubertal boys.
  • [MeSH-major] Continental Population Groups / statistics & numerical data. Neoplasms, Germ Cell and Embryonal / ethnology. Testicular Neoplasms / ethnology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Urol. 2008 Sep;180(3):1192-3
  • (PMID = 18355842.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD053943012
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


64. Luzzi L, Campione A, Gorla A, Vassallo G, Bianchi A, Biggi A, Terzi A: Role of fluorine-flurodeoxyglucose positron emission tomography/computed tomography in preoperative assessment of anterior mediastinal masses. Eur J Cardiothorac Surg; 2009 Sep;36(3):475-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: There were 13 thymomas (six LRT and seven HRT), three lymphomas and three other primitive thymic tumours (one paraganglioma, two non-seminomatous germ cell tumours).
  • The SUV in LRT was also significantly lower with respect to lymphoma, 12.4+/-4 (p=0.001), and the other primitive anterior mediastinal tumours, 8+/-0.8 (p=0.001).
  • [MeSH-major] Mediastinal Neoplasms / radiography. Mediastinal Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography / methods. Preoperative Care / methods. Radiopharmaceuticals. Thymoma / pathology. Thymoma / radiography. Thymoma / radionuclide imaging. Thymoma / surgery. Thymus Neoplasms / pathology. Thymus Neoplasms / radiography. Thymus Neoplasms / radionuclide imaging. Thymus Neoplasms / surgery. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19501523.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


65. Ahmed HU, Arya M, Muneer A, Mushtaq I, Sebire NJ: Testicular and paratesticular tumours in the prepubertal population. Lancet Oncol; 2010 May;11(5):476-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular and paratesticular tumours in the prepubertal population.
  • Prepubertal testicular and paratesticular tumours are a rare group of tumours, distinct from postpubertal paediatric and adult tumours of this region.
  • Tumours within this group are testicular germ-cell tumours (such as benign teratoma, epidermoid cyst and malignant yolk-sac tumours) and stromal tumours (such as juvenile granulosa-cell, Leydig-cell, and Sertoli-cell tumours).
  • Paratesticular tumours can be benign (lipoma, leiomyoma, haemangioma) or malignant (rhabdomyosarcoma, melanotic neuroectodermal tumour of infancy).
  • Because of their rarity, centralised pathology and treatment, and national collaborative clinical trials have been important in establishing the optimum management of malignant tumours in this group.
  • We provide an up-to-date and comprehensive review of the clinical presentation, imaging, pathology, and clinical management of prepubertal paratesticular and testicular tumours.
  • [MeSH-major] Genital Neoplasms, Male / diagnosis. Genital Neoplasms, Male / therapy
  • [MeSH-minor] Child. Combined Modality Therapy. Humans. Male. Neoplasm Staging. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / epidemiology. Neoplasms, Germ Cell and Embryonal / therapy. Sex Cord-Gonadal Stromal Tumors / diagnosis. Sex Cord-Gonadal Stromal Tumors / epidemiology. Sex Cord-Gonadal Stromal Tumors / therapy. Testicular Neoplasms / diagnosis. Testicular Neoplasms / epidemiology. Testicular Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • [CommentIn] Lancet Oncol. 2010 Sep;11(9):814 [20816371.001]
  • (PMID = 20434716.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0701302; United Kingdom / Medical Research Council / / G1002509
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 62
  •  go-up   go-down


66. Cheung WY, Demers A, Hossain D, Owen T, Ahmed S, Czaykowski PM: Appropriateness of testicular cancer management: a population-based cohort study. Can J Urol; 2007 Jun;14(3):3542-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Seventy-eight men were identified with 80 testicular cancers: 46 (59%) patients had 48 seminomas and 32 (41%) had non-seminomatous germ cell tumors (NSGCT).
  • One or more pre-operative tumor markers were missing or unavailable in 41 (52%) cases.
  • [MeSH-major] Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Combined Modality Therapy. Humans. Male. Manitoba / epidemiology. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Orchiectomy. Population Surveillance. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594744.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


67. Neyer M, Peschel R, Akkad T, Springer-Stöhr B, Berger A, Bartsch G, Steiner H: Long-term results of laparoscopic retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testicular cancer. J Endourol; 2007 Feb;21(2):180-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of laparoscopic retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testicular cancer.
  • PURPOSE: To report the long-term oncologic outcome and morbidity of laparoscopic retroperitoneal lymph-node dissection (L-RPLND) in clinical stage I nonseminomatous testicular germ-cell tumors (NSGCT) from a single institution.
  • None of the patients died because of tumor progression.

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17338618.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Hersmus R, de Leeuw BH, Wolffenbuttel KP, Drop SL, Oosterhuis JW, Cools M, Looijenga LH: New insights into type II germ cell tumor pathogenesis based on studies of patients with various forms of disorders of sex development (DSD). Mol Cell Endocrinol; 2008 Sep 10;291(1-2):1-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New insights into type II germ cell tumor pathogenesis based on studies of patients with various forms of disorders of sex development (DSD).
  • Patients with specific variants of this disorder have an elevated risk for the development of so-called type II germ cell cancers, i.e., the seminomatous and nonseminatous tumors, referred to as germ cell tumors (GCTs).
  • A prerequisite for type II GCT formation is the presence of a specific part of the Y chromosome (referred to as the GBY region), with the TSPY gene being the most likely candidate.
  • Also the octamer binding transcription factor OCT3/4 is consistently expressed in all type II GCTs with pluripotent potential, as well as in the precursor lesions carcinoma in situ (CIS) in case of a testis and gonadoblastoma (GB) in the DSD gonad.
  • The actual risk for malignant transformation in individual DSD patients is hard to predict, because of confusing terminology referring to the different forms of DSD, and unclear criteria for identification of the presence of malignant germ cells, especially in young patients.
  • This is specifically due to the phenomenon of delay of germ cell maturation, which might result in over diagnosis.
  • To allow optimal understanding of the pathogenesis of this type of cancers, first normal gonadal development, especially regarding the germ cell lineage, will be discussed, after which type II GCTs will be introduced.
  • Subsequently, the relationship between type II GCTs and DSD will be described, resulting in a number of new insights into the development of the precursor lesions of these tumors.
  • [MeSH-major] Disorders of Sex Development / complications. Disorders of Sex Development / pathology. Neoplasms, Germ Cell and Embryonal / etiology. Neoplasms, Germ Cell and Embryonal / pathology. Sexual Development / physiology
  • [MeSH-minor] Female. Genetic Predisposition to Disease. Germ Cells / physiology. Humans. Male. Risk Factors. Testicular Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18403106.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 87
  •  go-up   go-down


69. Marina N, London WB, Frazier AL, Lauer S, Rescorla F, Cushing B, Malogolowkin MH, Castleberry RP, Womer RB, Olson T: Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. J Clin Oncol; 2006 Jun 1;24(16):2544-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study.
  • PURPOSE: To investigate prognostic factors for pediatric extragonadal malignant germ cell tumors (PEMGCT).
  • There were 30 stage I/II, 61 stage III, and 74 stage IV tumors; primary sites included 88 sacrococcygeal, 39 thoracic, and 38 others.
  • Patients > or = 12 years of age with thoracic tumors had six times the risk of death compared with patients younger than 12 years with other primaries.
  • There is a significant interaction between age and primary site, suggesting that patients > or = 12 years of age with thoracic tumors are a biologically distinct group.
  • [MeSH-major] Germinoma / diagnosis
  • [MeSH-minor] Adolescent. Age Factors. Analysis of Variance. Biomarkers, Tumor / blood. Child. Disease-Free Survival. Female. Humans. Male. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Factors. Survival Analysis. alpha-Fetoproteins / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735707.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


70. Bandarchi B, Ma L, Marginean C, Hafezi S, Zubovits J, Rasty G: D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans. Mod Pathol; 2010 Mar;23(3):434-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • D2-40 identifies a 40-kDa O-linked sialoglycoprotein present on a variety of tissues including testicular germ cell tumors as well as lymphatic endothelium.
  • All 56 (100%) cases of dermatofibroma demonstrated strong and diffuse immunoreactivity to D2-40 in the spindle cells and stroma.
  • Similarly, factor XIIIa showed strong and diffuse positivity in the spindle cells.
  • [MeSH-major] Antibodies, Monoclonal / analysis. Biomarkers, Tumor / analysis. Dermatofibrosarcoma / diagnosis. Histiocytoma, Benign Fibrous / diagnosis
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived. Antigens, CD34 / analysis. Diagnosis, Differential. Factor XIIIa / analysis. Humans. Immunohistochemistry. Mice. Stromal Cells / chemistry. Stromal Cells / pathology

  • Genetic Alliance. consumer health - Dermatofibroma.
  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20062007.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40; EC 2.3.2.13 / Factor XIIIa
  •  go-up   go-down


71. Kondagunta GV, Bacik J, Bajorin D, Dobrzynski D, Sheinfeld J, Motzer RJ, Bosl GJ: Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol; 2005 Dec 20;23(36):9290-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors.
  • PURPOSE: To assess response, overall survival, and relapse-free survival of patients with good-risk metastatic germ cell tumor (GCT) by International Germ Cell Consensus Classification Group (IGCCCG) criteria treated with four cycles of etoposide and cisplatin (EP).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Retroperitoneal Neoplasms / drug therapy. Testicular Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Jun 1;24(16):2597-8; author reply 2598-9 [16735718.001]
  • (PMID = 16361627.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5T32-CA-09207-26
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; VP-P protocol
  •  go-up   go-down


72. Kesic V: Fertility after the treatment of gynecologic tumors. Recent Results Cancer Res; 2008;178:79-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility after the treatment of gynecologic tumors.
  • Fertility-sparing surgery may be safe in early ovarian cancer of certain histological subtypes such as ovarian tumors of low malignant potential, malignant ovarian germ cell tumors, and ovarian sex cord stromal tumors.
  • Gynecologic surgery and hemotherapy can have an impact not only on fertility, but also on the course of a next pregnancy (increased risk of miscarriage and premature delivery, etc.
  • [MeSH-major] Fertility / physiology. Infertility, Female / prevention & control. Ovarian Neoplasms / therapy. Pregnancy Complications, Neoplastic. Pregnancy Outcome

  • MedlinePlus Health Information. consumer health - Female Infertility.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18080446.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 64
  •  go-up   go-down


73. Alston RD, Rowan S, Eden TO, Moran A, Birch JM: Cancer incidence patterns by region and socioeconomic deprivation in teenagers and young adults in England. Br J Cancer; 2007 Jun 4;96(11):1760-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of leukaemia, lymphoma, central nervous system tumours, soft tissue sarcomas, gonadal germ cell tumours, melanoma and carcinomas varied by region (P<0.01, all groups) but bone tumour incidence did not.
  • Lymphomas, central nervous system tumours and gonadal germ cell tumours all had higher incidence in less deprived census wards (P<0.01), while chronic myeloid leukaemia and carcinoma of the cervix had higher incidence in more deprived wards (P<0.01).
  • [MeSH-major] Geography. Neoplasms / epidemiology. Neoplasms / etiology. Psychosocial Deprivation
  • [MeSH-minor] Adolescent. Adult. Bone Neoplasms / epidemiology. Brain Neoplasms / epidemiology. Carcinoma / epidemiology. England / epidemiology. Female. Humans. Incidence. Leukemia / epidemiology. Lymphoma / epidemiology. Male. Melanoma / epidemiology. Neoplasms, Germ Cell and Embryonal / epidemiology. Sarcoma / epidemiology. Socioeconomic Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Oncol. 2000 Sep;12(5):383-94 [10975544.001]
  • [Cites] Leuk Lymphoma. 2006 Apr;47(4):583-98 [16690516.001]
  • [Cites] APMIS. 2003 Jan;111(1):43-6; discussion 46-8 [12752232.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3042-52 [12789279.001]
  • [Cites] Am J Epidemiol. 2003 Aug 15;158(4):328-36 [12915498.001]
  • [Cites] Clin Exp Dermatol. 2004 May;29(3):328-30 [15115532.001]
  • [Cites] Int J Cancer. 1991 Apr 22;48(1):10-4 [2019450.001]
  • [Cites] Br J Cancer. 1992 Aug;66(2):408-13 [1503917.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):973-9 [7947107.001]
  • [Cites] Ann Oncol. 1996;7 Suppl 4:5-10 [8836402.001]
  • [Cites] Int J Cancer. 1997 Feb 7;70(4):375-82 [9033642.001]
  • [Cites] Int Arch Occup Environ Health. 1997;70(1):57-60 [9258708.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] BMJ. 2005 Jan 29;330(7485):223 [15613366.001]
  • [Cites] Chem Biol Interact. 2005 May 30;153-154:9-21 [15935796.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):906-16 [15956652.001]
  • [Cites] Br J Cancer. 2002 Nov 18;87(11):1267-74 [12439716.001]
  • (PMID = 17505509.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2359909
  •  go-up   go-down


74. De Giorgi U, Demirer T, Wandt H, Taverna C, Siegert W, Bornhauser M, Kozak T, Papiani G, Ballardini M, Rosti G, Solid Tumor Working Party of the European Group for Blood and Marrow Transplantation: Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience. Ann Oncol; 2005 Jan;16(1):146-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience.
  • BACKGROUND: Results of second-line chemotherapy in patients with extragonadal non-seminomatous germ cell tumor (NSGCT) appear inferior to results in testicular NSGCT.

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15598952.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


75. Bulletin board. Study suggests that following surgery, watchful waiting may be a safe option for girls with early-stage ovarian germ cell tumors. Future Oncol; 2010 Dec;6(12):1825
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bulletin board. Study suggests that following surgery, watchful waiting may be a safe option for girls with early-stage ovarian germ cell tumors.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Female. Humans. Neoplasm Recurrence, Local. Neoplasm Staging. Watchful Waiting

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21188885.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] England
  •  go-up   go-down


76. Jahnke K, Kraemer DF, Knight KR, Fortin D, Bell S, Doolittle ND, Muldoon LL, Neuwelt EA: Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system. Cancer; 2008 Feb 1;112(3):581-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
  • BACKGROUND: The rate of durable responses in embryonal and certain germ cell tumors of the central nervous system (CNS) is unsatisfactory.
  • The median OS was 2.8 years for all patients, 2.5 years for supratentorial and disseminated primitive neuroectodermal tumors (PNETs, n = 29), 1.7 years for medulloblastomas (n = 12), and 5.4 years for germ cell tumors (n = 13).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood-Brain Barrier / physiopathology. Central Nervous System Neoplasms / drug therapy. Neoplasms, Germ Cell and Embryonal / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18072268.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS33618; United States / NINDS NIH HHS / NS / NS44687
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


77. Lau SK, Chang KL: OCT4: a sensitive and specific immunohistochemical marker for metastatic germ cell tumors. Adv Anat Pathol; 2006 Mar;13(2):76-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] OCT4: a sensitive and specific immunohistochemical marker for metastatic germ cell tumors.
  • [MeSH-major] Antibodies, Monoclonal / analysis. Biomarkers, Tumor / analysis. Immunohistochemistry. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Unknown Primary / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Embryonal / diagnosis. Carcinoma, Embryonal / metabolism. Choriocarcinoma / diagnosis. Choriocarcinoma / metabolism. Diagnosis, Differential. Humans. Male. Neuroectodermal Tumors / diagnosis. Neuroectodermal Tumors / metabolism. Seminoma / diagnosis. Seminoma / metabolism. Teratoma / diagnosis. Teratoma / metabolism

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670461.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / OKT4A monoclonal antibody
  •  go-up   go-down


78. Jankilevich G, Mendizabal J, Massa MA, Pedernera A, Galmes M, Spizzamiglio N: [Mediastinal sarcoidal reaction in follow up for seminoma]. Medicina (B Aires); 2006;66(6):552-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Reaccion sarcoidal mediastinal en el seguimiento de un paciente con seminoma.
  • Testicular germ cell tumors constitute a model for curable neoplasia.
  • Long-term complications are well-known and follow-up includes not only awareness of relapse, but also of the development of secondary tumors and treatment sequelae.
  • A 28 year-old patient who, on clinical follow up of a semi-nomatous tumor, presented mediastinal lymph nodes on CT scan and chest x-ray, without evidence of disease in pelvis or abdomen is presented.
  • His other testicle was normal and he had negative tumor markers.
  • During follow-up of patients with testicular germ cell tumors, the presence of mediastinal lymph nodes requires a histological diagnosis and sarcoidosis should be considered as differential diagnosis.
  • [MeSH-major] Mediastinal Diseases / etiology. Sarcoidosis / etiology. Seminoma / complications. Testicular Neoplasms / complications
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Male. Mediastinum / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Prognosis

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17240627.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


79. Zivanovic O, Sheinfeld J, Abu-Rustum NR: Retroperitoneal lymph node dissection (RPLND). Gynecol Oncol; 2008 Nov;111(2 Suppl):S66-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pelvic and paraaortic lymph nodes are common sites of metastases from gynecologic malignancies and may act as a sanctuary of chemoresistant tumor cells in some patients.
  • Furthermore, RPLND is an important aspect of post-chemotherapy debulking surgery for nonseminomatous germ cell tumors, which is the counterpart of the ovarian immature teratoma.
  • [MeSH-major] Genital Neoplasms, Female / pathology. Genital Neoplasms, Female / surgery. Lymph Node Excision / methods. Lymph Nodes / anatomy & histology. Lymph Nodes / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18789513.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Chua TC, Koong HN: Curative pulmonary metastasectomy for non-seminomatous germ cell tumor of the testis. ANZ J Surg; 2010 May;80(5):380-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curative pulmonary metastasectomy for non-seminomatous germ cell tumor of the testis.
  • [MeSH-major] Lung Neoplasms / secondary. Lung Neoplasms / surgery. Neoplasms, Germ Cell and Embryonal / secondary. Neoplasms, Germ Cell and Embryonal / surgery. Pneumonectomy. Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20557524.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Australia
  •  go-up   go-down


81. Haibin Z, Yue J, Yaxian X: Primary yolk sac tumor of the omentum: a case report and literature review. Eur J Gynaecol Oncol; 2010;31(6):682-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary yolk sac tumor of the omentum: a case report and literature review.
  • BACKGROUND: Yolk sac tumor (YST) is the second most common malignant ovarian germ cell tumor, while a YST arising in the omentum is an exceedingly rare malignancy.
  • CASE: A 44-year-old woman was admitted with a history of abdominal distension of a month's duration.
  • The case of omental YST must be seriously considered once the tumor shows omentum thickening with elevated AFP serum levels.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / therapy. Omentum / surgery. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21319517.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


82. Rustin GJ, Mead GM, Stenning SP, Vasey PA, Aass N, Huddart RA, Sokal MP, Joffe JK, Harland SJ, Kirk SJ, National Cancer Research Institute Testis Cancer Clinical Studies Group: Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol; 2007 Apr 10;25(11):1310-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group.
  • PURPOSE: Surveillance is a standard management approach for stage I nonseminomatous germ cell tumors (NSGCT).
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / diagnostic imaging. Testicular Neoplasms / diagnostic imaging. Tomography, X-Ray Computed / utilization
  • [MeSH-minor] Adult. Australia / epidemiology. Chi-Square Distribution. Disease Progression. Humans. Male. Neoplasm Recurrence, Local. Neoplasm Staging. New Zealand / epidemiology. Norway / epidemiology. Prognosis. Randomized Controlled Trials as Topic. United Kingdom / epidemiology

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Apr 10;25(11):1308-9 [17416850.001]
  • (PMID = 17416851.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN56475197
  • [Grant] United Kingdom / Medical Research Council / / MC/ U122861331
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


83. Rondinelli PI, Osório CA, Lopes LF: [Primary intracranial germ cell tumors in children: evaluation of fourteen cases]. Arq Neuropsiquiatr; 2005 Sep;63(3B):832-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary intracranial germ cell tumors in children: evaluation of fourteen cases].
  • [Transliterated title] Tumores de células germinativas intracranianos na infância: avaliação de 14 casos.
  • This study evaluates the diagnosis, therapy and survival of 14 patients with primary intracranial germ cell tumors during the period from 1991 to 2001.
  • The tumor was in pineal and hypothalamic region in 10 cases, suprasellar in 3 cases, and in the cerebral parenchyma in 1 case.
  • Histologically there were 1 embryonal carcinoma, 5 germinomas, 2 mature teratomas, 1 immature teratoma and 5 mixed germ cell tumors.
  • Treatment differed among the patients according to the type of tumor.
  • Three patients died after tumor progression or relapse and one patient died from another condition.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258665.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


84. Browne CM, Hime GR, Koopman P, Loveland KL: Genetic basis of human testicular germ cell cancer: insights from the fruitfly and mouse. Cell Tissue Res; 2005 Oct;322(1):5-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic basis of human testicular germ cell cancer: insights from the fruitfly and mouse.
  • The prevalence of tumours of the germ line is increasing in the male population.
  • We examine the contribution of genetic mutations to the development of germ line tumours in this review.
  • In particular, we concentrate on fly and mouse experimental systems in order to demonstrate that mutations in some conserved genes cause pathologies typical of certain human germ cell tumours, whereas other mutations elicit phenotypes that are unique to the experimental model.
  • Despite these experimental systems being imperfect, we show that they are useful models of human testicular germ cell tumourigenesis.
  • [MeSH-major] Drosophila. Mice. Neoplasms, Germ Cell and Embryonal / genetics. Testicular Neoplasms / genetics

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • FlyBase. FlyBase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094543.001).
  • [ISSN] 0302-766X
  • [Journal-full-title] Cell and tissue research
  • [ISO-abbreviation] Cell Tissue Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 162
  •  go-up   go-down


85. Villano JL, Propp JM, Porter KR, Stewart AK, Valyi-Nagy T, Li X, Engelhard HH, McCarthy BJ: Malignant pineal germ-cell tumors: an analysis of cases from three tumor registries. Neuro Oncol; 2008 Apr;10(2):121-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pineal germ-cell tumors: an analysis of cases from three tumor registries.
  • The exact incidence of pineal germ-cell tumors is largely unknown.
  • The tumors are rare, and the number of patients with these tumors, as reported in clinical series, has been limited.
  • The goal of this study was to describe pineal germ-cell tumors in a large number of patients, using data from available brain tumor databases.
  • Three different databases were used: Surveillance, Epidemiology, and End Results (SEER) database (1973-2001); Central Brain Tumor Registry of the United States (CBTRUS; 1997-2001); and National Cancer Data Base (NCDB; 1985-2003).
  • Tumors were identified using the International Classification of Diseases for Oncology, third edition (ICD-O-3), site code C75.3, and categorized according to histology codes 9060-9085.
  • A total of 1,467 cases of malignant pineal germ-cell tumors were identified: 1,159 from NCDB, 196 from SEER, and 112 from CBTRUS.
  • All three databases showed a male predominance for pineal germ-cell tumors (>90%), and >72% of patients were Caucasian.
  • The majority of tumors (73%-86%) were germinomas, and patients with germinomas had the highest survival rate (>79% at 5 years).
  • The proportions of malignant pineal germ-cell tumors and intracranial germ-cell tumors are in range with previous studies.
  • Survival rates for malignant pineal germ-cell tumors are lower than results from recent treatment trials for intracranial germ-cell tumors, and patients that received radiation therapy in the treatment plan either with surgery or alone survived the longest.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / epidemiology. Neoplasms, Germ Cell and Embryonal / therapy. Pinealoma / epidemiology. Pinealoma / therapy. Registries

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):815-21 [11005262.001]
  • [Cites] Childs Nerv Syst. 1999 Mar;15(2-3):119-26; discussion 127 [10230668.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):857-65 [11821471.001]
  • [Cites] Pediatr Blood Cancer. 2004 Aug;43(2):126-33 [15236278.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64(4):407-29 [5318716.001]
  • [Cites] Am J Clin Pathol. 1976 Apr;65(4):450-4 [178171.001]
  • [Cites] J Neurosurg. 1979 Nov;51(5):597-607 [501398.001]
  • [Cites] Cancer. 1981 Nov 1;48(9):2038-46 [7296511.001]
  • [Cites] J Neurosurg. 1985 Aug;63(2):155-67 [2991485.001]
  • [Cites] J Neurosurg. 1985 Sep;63(3):321-41 [2862230.001]
  • [Cites] N Engl J Med. 1987 Jun 4;316(23):1435-40 [2437455.001]
  • [Cites] Pediatr Pathol. 1990;10(1-2):231-41 [2156245.001]
  • [Cites] J Urol. 1990 Nov;144(5):1160-3 [2172569.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):545-51 [1848284.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Dec;5(6):1189-209 [1663939.001]
  • [Cites] Semin Oncol. 1992 Apr;19(2):119-27 [1313190.001]
  • [Cites] Neurosurg Clin N Am. 1992 Oct;3(4):853-62 [1392580.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):229-45 [8270446.001]
  • [Cites] Neuropediatrics. 1994 Feb;25(1):26-32 [8208347.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):943-9 [7607968.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2908-15 [8918487.001]
  • [Cites] Phys Med Biol. 1997 Jan;42(1):123-32 [9015813.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] Cancer. 1997 May 15;79(10):2052-61 [9149035.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2296-304 [9404707.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):41-8 [9548340.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):258-64 [9950496.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):933-40 [10071287.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1199-204 [10098759.001]
  • [Cites] Int J Clin Oncol. 2001 Aug;6(4):183-91 [11706556.001]
  • (PMID = 18287340.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2613814
  •  go-up   go-down


86. Gilbert DC, Norman AR, Nicholl J, Dearnaley DP, Horwich A, Huddart RA: Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy. BJU Int; 2006 Jul;98(1):67-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy.
  • OBJECTIVE: To estimate the rate of relapse in men with stage I nonseminomatous germ cell tumours (NSGCT) of the testis treated with one cycle of chemotherapy instead of the usual two cycles.
  • PATIENTS AND METHODS: Between 1992 and 1996, 22 men with stage I NSGCT who had normalized tumour markers after orchidectomy and negative findings on computed tomography, and who were at moderate risk of relapse, were treated with one cycle of platinum-containing chemotherapy (bleomycin and etoposide with either cisplatin or carboplatin).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / etiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831145.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


87. May M, Finkbeiner Y, Gunia S, Seehafer M, Knörig J, Hetzer R: Metastasizing testicular germ-cell tumor with infiltration of the right heart: indication for primary metastasectomy. Heart Vessels; 2006 Jan;21(1):63-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasizing testicular germ-cell tumor with infiltration of the right heart: indication for primary metastasectomy.
  • The case of a 42-year-old male patient with a testicular germ cell tumor extending into the superior caval vein, the left brachiocephalic vein, and the right heart, which manifested as a mild form of pulmonary embolization, is presented.
  • Due to the perceived high risk of continuous embolization and the urgent need to begin systemic chemotherapy, a complete cardiac tumor resection was performed, utilizing a cardiopulmonary bypass, followed by a simultaneous orchiectomy.
  • Histology revealed a 61-cm long vascular tumor as a metastasis of a yolk sac tumor originating from the left testis.
  • There were no postoperative complications, and the patient is alive and without tumor recurrence 12 months after four cycles of systemic chemotherapy according to the PEB (cisplatin, etoposide, bleomycin) scheme.
  • We conclude that in this special case aggressive surgical management following chemotherapy was very effective in controlling the disseminated testicular tumor.
  • [MeSH-major] Endodermal Sinus Tumor / secondary. Endodermal Sinus Tumor / surgery. Heart Neoplasms / secondary. Heart Neoplasms / surgery. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Heart tumor.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ind Med. 2004 Jan;45(1):24-33 [14691966.001]
  • [Cites] Ann Thorac Surg. 2002 May;73(5):1631-3 [12022566.001]
  • [Cites] Clin Cardiol. 1999 Jun;22(6):429-33 [10376186.001]
  • [Cites] J Urol. 1993 Jan;149(1):129-31 [8417194.001]
  • [Cites] Urology. 1995 Dec;46(6):883-7 [7502438.001]
  • [Cites] Heart Vessels. 2004 May;19(3):121-4 [15168059.001]
  • [Cites] Am J Cardiol. 1997 Sep 1;80(5):671-82 [9295010.001]
  • [Cites] Nihon Kyobu Geka Gakkai Zasshi. 1991 Oct;39(10):1966-70 [1960446.001]
  • (PMID = 16440152.001).
  • [ISSN] 0910-8327
  • [Journal-full-title] Heart and vessels
  • [ISO-abbreviation] Heart Vessels
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


88. Palmer RD, Barbosa-Morais NL, Gooding EL, Muralidhar B, Thornton CM, Pett MR, Roberts I, Schneider DT, Thorne N, Tavaré S, Nicholson JC, Coleman N, Children's Cancer and Leukaemia Group: Pediatric malignant germ cell tumors show characteristic transcriptome profiles. Cancer Res; 2008 Jun 01;68(11):4239-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric malignant germ cell tumors show characteristic transcriptome profiles.
  • Malignant germ cell tumors (GCT) of childhood are rare and heterogeneous neoplasms thought to arise from primordial germ cells.
  • Our study included 27 primary tumors and assessed the principal malignant histologic types of pediatric GCT, yolk sac tumor (YST; n = 18), and seminoma (n = 9).
  • There was no segregation of tumors of the same histology arising at different sites or at different ages within the pediatric range.
  • [MeSH-major] Endodermal Sinus Tumor / genetics. Gene Expression Profiling. Neoplasms, Germ Cell and Embryonal / genetics. RNA, Messenger / genetics. Seminoma / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18519683.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Databank-accession-numbers] GEO/ GSE10615
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105359875; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


89. Lotz JP, Bui B, Gomez F, Théodore C, Caty A, Fizazi K, Gravis G, Delva R, Peny J, Viens P, Duclos B, De Revel T, Curé H, Gligorov J, Guillemaut S, Ségura C, Provent S, Droz JP, Culine S, Biron P, Groupe d'Etudes des Tumeurs Uro-Génitales (GETUG): Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. Ann Oncol; 2005 Mar;16(3):411-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial.
  • BACKGROUND: High-dose chemotherapy (HD-CT) is able to circumvent platinum resistance of resistant/refractory germ-cell tumors (GCTs), but expectancy of cure remains low.
  • MATERIALS AND METHODS: Patients with relapsed poor-prognosis GCTs were scheduled to receive two cycles combining epirubicin and paclitaxel (Taxol) followed by three consecutive HD-CT supported by stem cell transplantation [one course combining cyclophosphamide, 3 g/m(2) + thiotepa, 400 mg/m(2), followed by two ICE regimens (ifosfamide, 10 g/m(2), carboplatin, AUC 20, etoposide, 1500 mg/m(2))].

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15659420.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


90. Piskareva O, Clynes M, Barron N: Detection and cloning of LINE-1 elements in CHO cells. Cytotechnology; 2007 Apr;53(1-3):75-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and cloning of LINE-1 elements in CHO cells.
  • L1-encoded products have been detected in a number of tissues including mammalian germ cell tumours, breast carcinomas and a large variety of transformed mouse and human cell lines.Chinese Hamster Ovary (CHO) cells are widely used in the manufacture of recombinant proteins for biopharmaceuticals.
  • Here, we investigated the transcriptional activity of hamster L1 elements in CHO-K1 cells.
  • These cells were analysed for the presence of L1 RNA transcripts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2006 Jan 23;580(2):661-8 [16412437.001]
  • [Cites] Mol Biol Evol. 1999 Jun;16(6):793-805 [10368957.001]
  • [Cites] Dev Biol Stand. 1992;76:201-7 [1282476.001]
  • [Cites] Mol Biol Evol. 2000 Jun;17(6):915-28 [10833198.001]
  • [Cites] Dev Biol Stand. 1991;75:113-22 [1665458.001]
  • [Cites] Annu Rev Genet. 2001;35:501-38 [11700292.001]
  • [Cites] Biologicals. 2000 Sep;28(3):137-48 [10964440.001]
  • [Cites] Virology. 1991 Mar;181(1):305-11 [1704658.001]
  • (PMID = 19003192.001).
  • [ISSN] 0920-9069
  • [Journal-full-title] Cytotechnology
  • [ISO-abbreviation] Cytotechnology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2267621
  •  go-up   go-down


91. Went PT, Dirnhofer S, Stallmach T, Taverna C, Singer G: Placental site trophoblastic tumor of the mediastinum. Hum Pathol; 2005 May;36(5):581-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental site trophoblastic tumor of the mediastinum.
  • Choriocarcinoma has been described as the most frequent subtype of mediastinal germ cell tumors showing trophoblastic differentiation.
  • We report a unique case of a placental site trophoblastic tumor, which developed in the mediastinum of a 14-year-old boy 2 years after the resection of a mature teratoma.
  • The recurrent tumor was composed of a grossly hemorrhagic and necrotic mass.
  • Histologically, diffusely infiltrating large polygonal cells with focal nodular growth and a teratomatous part containing mature intestinal, respiratory, and squamous epithelium with adjacent cutaneous adnexal structures were found.
  • The typical morphologic features included vessel wall infiltration by the neoplastic cells with fibrinoid deposits and geographic necroses within the tumor masses.
  • Characteristic diffuse positivity for melanoma cell adhesion molecule and human leucocyte antigen G was found on immunohistochemical investigation, confirming the diagnosis of placental site trophoblastic tumor.
  • The outcome of this rare tumor is similar to the reported poor clinical outcome in patients with mediastinal choriocarcinomas.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Trophoblastic Tumor, Placental Site / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948127.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Ra YJ, Bae MJ, Kim YS, Choi KU: Difficulties in diagnosis and treatment of thymic adenocarcinoma producing beta-human chorionic gonadotropin in anterior mediastinum. Interact Cardiovasc Thorac Surg; 2010 Jul;11(1):114-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Difficulties in diagnosis and treatment of thymic adenocarcinoma producing beta-human chorionic gonadotropin in anterior mediastinum.
  • Since the beta-human chorionic gonadotropin (beta-hCG) level was increased to 20.46 mIU/ml on the preoperative blood test, incisional biopsy was performed through a Chamberlain incision to rule out the mediastinal germ cell tumors.
  • On the pathological examination after the second operation, the tumor was diagnosed as thymic adenocarcinoma producing beta-hCG, and the tumor had originated from the thymus.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Biomarkers, Tumor / blood. Chorionic Gonadotropin, beta Subunit, Human / blood. Mediastinal Neoplasms / secondary. Mediastinal Neoplasms / surgery. Thoracic Surgical Procedures. Thymus Neoplasms / pathology. Thymus Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20421278.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human
  •  go-up   go-down


93. Albers P: Surgery is an essential part of salvage treatment in refractory germ cell tumors. Eur Urol; 2006 Nov;50(5):893-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery is an essential part of salvage treatment in refractory germ cell tumors.
  • [MeSH-major] Drug Resistance, Neoplasm. Neoplasms, Germ Cell and Embryonal / surgery. Salvage Therapy / methods

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Eur Urol. 2006 Nov;50(5):1032-8; discussion 1038-9 [16757095.001]
  • (PMID = 16753254.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


94. Kempkensteffen C, Hinz S, Jäger T, Weikert S, Krause H, Schostak M, Christoph F, Strenziok R, Miller K, Schrader M: [Expression levels of the IAP antagonists XAF1, Smac/DIABLO and HtrA2 in testicular germ cell tumours]. Aktuelle Urol; 2008 Nov;39(6):436-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression levels of the IAP antagonists XAF1, Smac/DIABLO and HtrA2 in testicular germ cell tumours].
  • [Transliterated title] Expression der pro-apoptotischen Apoptoseinhibitor-(IAP)Antagonisten XAF1, Smac/DIABLO und HtrA2 in Keimzelltumoren des Hodens.
  • We examined the mRNA-expression of these pro-apoptotic parameters in testicular germ cell tumors (TGCT) and normal testicular tissue and correlated their expression levels to clinicopathological tumour features.
  • MATERIAL AND METHODS: Real-time RT-PCR was used to quantify the mRNA-expression of XAF1, Smac/DIABLO and HtrA2 in normal testicular tissue (n = 18), carcinoma in situ (n = 4), seminomas (n = 64), and non-seminomatous germ cell tumors (n = 35).
  • Moreover, XAF1 and HtrA2 expression levels gradually increased with progression of clinical tumour stage in seminoma patients (p = 0.001 and p = 0.018), their expression levels being strongly intercorrelated (Spearman rho correlation coefficient: 0.674; p < 0.001).
  • Regarding the additional correlation of XAF1 and HtrA2 expression with clinical tumour stage in seminoma patients, it appears reasonable to further evaluate these three IAP antagonists as molecular parameters for the prediction of treatment response and prognosis of TGCT patients.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / genetics. Inhibitor of Apoptosis Proteins / antagonists & inhibitors. Inhibitor of Apoptosis Proteins / genetics. Intracellular Signaling Peptides and Proteins / genetics. Mitochondrial Proteins / genetics. Neoplasm Proteins / genetics. Neoplasms, Germ Cell and Embryonal / genetics. Serine Endopeptidases / genetics. Testicular Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18979398.001).
  • [ISSN] 1438-8820
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DIABLO protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / XAF1 protein, human; EC 3.4.21.- / Omi serine protease; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


95. Lee JW, Yang WS, Chung SY, Kang JH, Cho B, Kim HK, Kim KM, Jeong DC: Aggressive systemic mastocytosis after germ cell tumor of the ovary: C-KIT mutation documentation in both disease states. J Pediatr Hematol Oncol; 2007 Jun;29(6):412-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive systemic mastocytosis after germ cell tumor of the ovary: C-KIT mutation documentation in both disease states.
  • We report a case of aggressive systemic mastocytosis in a 3-year-old girl, who had undergone treatment for ovarian germ cell tumor during the previous 8 months.
  • On diagnosis of systemic mastocytosis, she was treated with interferon-alpha and steroids.
  • Point mutations of the C-KIT gene, previously implicated in the genesis of mastocytosis, were discovered not only in the bone marrow and the peripheral blood of the patient, but also in the tissue of the previously diagnosed germ cell tumor as well.
  • [MeSH-major] Mastocytosis, Systemic / genetics. Mutation. Neoplasms, Germ Cell and Embryonal / genetics. Ovarian Neoplasms / genetics. Proto-Oncogene Proteins c-kit / genetics


96. Fakhr IM, Khalil el-SA, El-Baradie TS, Shaalan MA, Shalaby LM, Nassif SL, Farahat IG: The role of surgical management in pediatric germ cell tumors (GCTs), NCI case series. J Egypt Natl Canc Inst; 2008 Mar;20(1):70-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of surgical management in pediatric germ cell tumors (GCTs), NCI case series.
  • PURPOSE: To review the experience of a tertiary referral center in pediatric germ cell tumors (GCTs) in the last 8 years and to investigate the impact of surgery and site of disease on prognosis.
  • PATIENTS AND METHODS: We retrospectively analyzed the cases of pediatric germ cell tumors at National Cancer Institute over an 8 years period.
  • Data concerning diagnosis, surgery and medical decisions were reviewed and analyzed for all patients.
  • Yolk sac tumor and malignant teratoma were the commonest histologic subtypes in our series.
  • CONCLUSION: The initial surgical approach to malignant GCTs at all sites should be complete resection when possible; the morbidity of extensive surgical resection should be weighed carefully against the good tumor control with chemotherapy.
  • The site of primary disease plays a role in the prognosis of pediatric germ cell tumors with the extragonadal pelvic tumors being the worst regarding resectability.
  • Good tumor response can be achieved with surgery and chemotherapy even for advanced stage and metastatic disease.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / surgery
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Humans. Infant. Lymphatic Metastasis. Male. Neoplasm Staging. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847284.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


97. Hoei-Hansen CE, Almstrup K, Nielsen JE, Brask Sonne S, Graem N, Skakkebaek NE, Leffers H, Rajpert-De Meyts E: Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours. Histopathology; 2005 Jul;47(1):48-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours.
  • AIMS: NANOG is a key regulator of embryonic stem cell (ESC) self-renewal and pluripotency.
  • Our recent genome-wide gene expression profiling study of the precursor of testicular germ cell tumours, carcinoma in situ testis (CIS), showed close similarity between ESC and CIS, including high NANOG expression.
  • METHODS AND RESULTS: We detected abundant expression of NANOG in CIS and in CIS-derived testicular tumours with marked differences; seminoma and embryonal carcinoma were strongly positive, differentiated somatic elements of teratoma were negative.
  • CONCLUSIONS: NANOG is a new marker for testicular CIS and germ cell tumours and the high level of NANOG along with OCT-4 are determinants of the stem cell-like pluripotency of the preinvasive CIS cell.
  • [MeSH-major] Carcinoma in Situ / pathology. DNA-Binding Proteins / analysis. Germinoma / pathology. Homeodomain Proteins / analysis. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Alkaline Phosphatase. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Child. Child, Preschool. Fetus. GPI-Linked Proteins. Gene Expression Regulation, Neoplastic. Gestational Age. Humans. Immunohistochemistry. In Situ Hybridization. Isoenzymes / analysis. Male. Octamer Transcription Factor-3. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factor AP-2. Transcription Factors / analysis

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982323.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / GPI-Linked Proteins; 0 / Homeodomain Proteins; 0 / Isoenzymes; 0 / NANOG protein, human; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human; 0 / RNA, Messenger; 0 / Transcription Factor AP-2; 0 / Transcription Factors; EC 3.1.3.1 / Alkaline Phosphatase; EC 3.1.3.1 / alkaline phosphatase, placental
  •  go-up   go-down


98. Alexander EJ, White IM, Horwich A: Update on management of seminoma. Indian J Urol; 2010 Jan-Mar;26(1):82-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Testicular germ cell tumors and, in particular, seminomas are exquisitely radiation and chemotherapy-sensitive and most presentations are highly curable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 May 1;35(2):293-8 [8635936.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2933-9 [8918490.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Am J Clin Oncol. 1997 Apr;20(2):196-201 [9124200.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1427-31 [9193335.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):321-6 [9308934.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1429-39 [9326912.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):290-4 [9440755.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1287-93 [9552027.001]
  • [Cites] Semin Oncol. 1998 Apr;25(2):160-73 [9562449.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):828-32 [9743309.001]
  • [Cites] N Engl J Med. 1999 Feb 4;340(5):351-7 [9929525.001]
  • [Cites] BJU Int. 1999 Apr;83(6):649-53 [10233573.001]
  • [Cites] Radiother Oncol. 1999 Apr;51(1):35-42 [10386715.001]
  • [Cites] Eur Urol. 1999 Dec;36(6):601-8 [10559615.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):823-7 [10597202.001]
  • [Cites] Urology. 2000 Jan;55(1):102-6 [10654903.001]
  • [Cites] J Urol. 2003 Jun;169(6):2126-8 [12771733.001]
  • [Cites] Ann Oncol. 2003 Jun;14(6):867-72 [12796024.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):640-7 [14726503.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2305-11 [15150576.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):736-40 [15708251.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1200-8 [15718317.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1152-9 [15928070.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Oct;5(5):869-74 [16221056.001]
  • [Cites] Ann Oncol. 2006 Feb;17(2):276-80 [16254023.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9290-4 [16361627.001]
  • [Cites] Lancet. 2006 Mar 4;367(9512):754-65 [16517276.001]
  • [Cites] Ann Oncol. 2007 May;18(5):917-24 [17351252.001]
  • [Cites] N Engl J Med. 2007 Jul 26;357(4):340-8 [17652649.001]
  • [Cites] N Engl J Med. 2007 Nov 29;357(22):2277-84 [18046031.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):853-8 [18164856.001]
  • [Cites] Eur Urol. 2008 Mar;53(3):497-513 [18191015.001]
  • [Cites] J Urol. 2008 Mar;179(3):936-40; discussion 940 [18207171.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5416-21 [18936476.001]
  • [Cites] Eur Urol. 2010 Mar;57(3):474-9 [19577354.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):509-11 [10080592.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3457-60 [10550142.001]
  • [Cites] Eur Urol. 2008 Mar;53(3):478-96 [18191324.001]
  • [Cites] Br J Cancer. 2008 Jun 17;98(12):1894-902 [18542063.001]
  • [Cites] J Natl Compr Canc Netw. 2009 Jun;7(6):672-93 [19555582.001]
  • [Cites] Radiother Oncol. 1992 Oct;25(2):97-102 [1438941.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(5):913-9 [1447034.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):887-96 [1555981.001]
  • [Cites] Br J Cancer. 1992 May;65(5):775-8 [1586607.001]
  • [Cites] Br J Cancer. 1990 Apr;61(4):639-43 [2109999.001]
  • [Cites] J Clin Oncol. 1990 Apr;8(4):741-50 [2179483.001]
  • [Cites] Br J Cancer. 1990 Jun;61(6):866-8 [2372488.001]
  • [Cites] J Clin Oncol. 1985 Oct;3(10):1325-32 [2413180.001]
  • [Cites] J Urol. 1987 Jun;137(6):1234-5 [2438431.001]
  • [Cites] J Clin Oncol. 1989 Mar;7(3):387-91 [2465391.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1150-6 [2666591.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] Radiother Oncol. 1989 Mar;14(3):203-8 [2710951.001]
  • [Cites] J Urol. 1988 Sep;140(3):618-20 [3411688.001]
  • [Cites] Cancer. 1987 Aug 15;60(4):772-6 [3594400.001]
  • [Cites] Br J Cancer. 1985 Jul;52(1):7-13 [3893507.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2255-62 [7666083.001]
  • [Cites] Br J Radiol. 1995 Apr;68(808):400-5 [7795977.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):447-53 [8120544.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1146 [10561173.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1623-9 [11104556.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1629-40 [11250991.001]
  • [Cites] Radiother Oncol. 2001 Apr;59(1):5-11 [11295200.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1859-63 [11919245.001]
  • [Cites] Urology. 2002 Aug;60(2):324-8 [12137835.001]
  • [Cites] Can J Urol. 2002 Oct;9(5):1637-40 [12431325.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):101-4 [11134201.001]
  • [Cites] Lancet. 2001 Mar 10;357(9258):739-45 [11253966.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):643-9 [11597804.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):297-301 [11773182.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):599-605 [12056711.001]
  • [Cites] J Urol. 2002 Nov;168(5):1975-9 [12394688.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4448-52 [12431967.001]
  • [Cites] Ann Oncol. 2003 Jan;14(1):91-6 [12488299.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1107-18 [12637478.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 15;28(2):373-9 [8276652.001]
  • [Cites] Ann Hematol. 1996 Jan;72(1):1-9 [8605273.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):454-60 [8636757.001]
  • [Cites] Ann Oncol. 1997 Jan;8(1):37-40 [9093705.001]
  • [Cites] Eur Urol. 1997;31(4):405-7 [9187898.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):829-35 [9291801.001]
  • [Cites] J Urol. 1997 Nov;158(5):1813-8 [9334609.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):702-6 [9469360.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2500-4 [9667270.001]
  • [Cites] Radiother Oncol. 1998 Aug;48(2):185-90 [9783890.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1101-6 [12637477.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1513-23 [12697875.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):108-14 [14701772.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1034-9 [15020605.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):683-7 [15266338.001]
  • [Cites] Eur J Radiol. 2005 May;54(2):284-8 [15837411.001]
  • [Cites] Lancet. 2005 Jul 23-29;366(9482):293-300 [16039331.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8717-23 [16260698.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):467-75 [16421423.001]
  • [Cites] Onkologie. 2006 Dec;29(12):592-8 [17202831.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4370-8 [17906202.001]
  • [Cites] Ann Oncol. 2008 Mar;19(3):443-7 [18048383.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Apr 30;29(1):3-8 [8175442.001]
  • [Cites] Radiother Oncol. 1994 Mar;30(3):193-8 [8209001.001]
  • [Cites] Eur J Cancer. 1993;29A(14):1931-4 [8280484.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):415-24 [8445415.001]
  • (PMID = 20535292.001).
  • [ISSN] 1998-3824
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2878445
  • [Keywords] NOTNLM ; Carboplatin / chemotherapy / orchidectomy / radiotherapy / seminoma / surgery / surveillance / testicular germ cell tumors
  •  go-up   go-down


99. Perimenis P, Athanasopoulos A, Geraghty J, Macdonagh R: Retroperitoneal seminoma with 'burned out' phenomenon in the testis. Int J Urol; 2005 Jan;12(1):115-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rare 'burned out' phenomenon in germ cell tumors is known as the presence of an extragonadal germ cell tumor without traces of neoplasm in the testis.
  • This condition is different and less common from the primary extragonadal germ cell malignancies.
  • These malignancies are treated surgically with or without adjuvant chemotherapy or radiotherapy and their prognosis is better than that of other types of primary extragonadal tumors.
  • [MeSH-major] Lymph Node Excision. Seminoma / diagnosis. Testicular Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661068.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


100. Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP, MRC TE19 collaborators and the EORTC 30982 collaborators: Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet; 2005 Jul 23-29;366(9482):293-300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Adjuvant radiotherapy is effective treatment for stage I seminoma, but is associated with a risk of late non-germ-cell cancer and cardiovascular events.
  • New, second primary testicular germ-cell tumours were reported in ten patients allocated irradiation (all after para-aortic strip field) and two allocated carboplatin (5-year event rate 1.96% [95% CI 1.0-3.8] vs 0.54% [0.1-2.1], p=0.04).
  • Although the absence of disease-related deaths and preliminary data indicating fewer second primary testicular germ-cell tumours favour carboplatin use, these findings need to be confirmed beyond 4 years' follow-up.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Seminoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local. Orchiectomy. Radiotherapy, Adjuvant. Survival Rate

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet. 2005 Jul 23-29;366(9482):267-8 [16039313.001]
  • [CommentIn] Nat Clin Pract Urol. 2005 Dec;2(12):586-7 [16474542.001]
  • (PMID = 16039331.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN27163214
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down






Advertisement